export type Language = 'en' | 'de' | 'fr' | 'es' | 'zh' | 'ar';

export const languages: { code: Language; name: string; flag: string; rtl?: boolean }[] = [
  { code: 'en', name: 'English', flag: 'üá¨üáß' },
  { code: 'de', name: 'Deutsch', flag: 'üá©üá™' },
  { code: 'fr', name: 'Fran√ßais', flag: 'üá´üá∑' },
  { code: 'es', name: 'Espa√±ol', flag: 'üá™üá∏' },
  { code: 'zh', name: '‰∏≠Êñá', flag: 'üá®üá≥' },
  { code: 'ar', name: 'ÿßŸÑÿπÿ±ÿ®Ÿäÿ©', flag: 'üá∏üá¶', rtl: true },
];

export const translations = {
  en: {
    nav: {
      services: 'Services',
      insights: 'Insights',
      about: 'About',
      contact: 'Contact',
    },
    hero: {
      tagline: 'EMEA Healthcare Market Research',
      title: 'EMEA Healthcare Market Research for Pharmaceutical Excellence',
      subtitle: 'Transform Physician & Hospital Insights into Strategic Intelligence Across UK, Europe & MENA Markets',
      valueProposition: 'We deliver comprehensive quantitative and qualitative market research services that transform clinical data into actionable pharmaceutical intelligence. Our specialized methodology captures authentic physician perspectives from NHS and private healthcare settings, hospital trends, and patient insights across UK, European, and MENA markets to power your drug development, market access, and commercial strategies.',
      serviceHighlights: [
        'UK NHS & Private Healthcare Research',
        'Pan-European Physician Surveys',
        'Qualitative KOL Interviews',
        'Multi-Country Data Analytics',
        'UK ‚Ä¢ Europe ‚Ä¢ MENA Coverage',
      ],
      cta: 'Get UK Research Proposal',
      ctaSecondary: 'View European Case Studies',
      trustBar: 'Trusted by pharmaceutical companies in',
      trustCountries: 'UK ‚Ä¢ Germany ‚Ä¢ France ‚Ä¢ Spain ‚Ä¢ Italy ‚Ä¢ UAE ‚Ä¢ Saudi Arabia ‚Ä¢ Egypt ‚Ä¢ Kuwait ‚Ä¢ Qatar',
      complianceBadges: ['MHRA Compliant', 'EMA Aligned', 'GDPR Compliant', 'SFDA Compliant', 'ICH-GCP'],
    },
    services: {
      title: 'Comprehensive Healthcare Market Research Services for UK & European Pharmaceutical Companies',
      subtitle: 'Quantitative and qualitative insights from physicians and hospitals across UK, Europe & MENA',
      items: [
        {
          title: 'Quantitative Healthcare Research & Physician Surveys',
          description: 'Large-scale statistical insights from physicians and healthcare professionals across UK, Europe, and MENA. Services: NHS and private provider research, hospital preference studies, prescription tracking, HTA decision-maker insights, payer analysis, multi-country surveys (UAE, Saudi Arabia, Egypt, Kuwait, Qatar). Deliverables: Statistical reports, market sizing, pathway analysis, forecasting, segmentation, comparative insights.',
        },
        {
          title: 'Qualitative Pharmaceutical Research & Expert Insights',
          description: 'Deep-dive qualitative research capturing clinical perspectives and unmet medical needs across UK, Europe, and MENA. Services: NHS consultant/GP interviews, NICE committee engagement, Pan-European KOL mapping, multi-country focus groups, treatment pathway analysis, Gulf healthcare insights. Deliverables: Thematic analysis, consensus summaries, market access recommendations, KOL strategies.',
        },
        {
          title: 'Market Access & HTA Strategy',
          description: 'NICE, G-BA, HAS and HTA body requirement integration. Evidence-based pricing strategies and payer engagement frameworks for UK and European markets. Reimbursement landscape modeling and cost-effectiveness analysis for HTA submissions.',
        },
        {
          title: 'KOL & Stakeholder Mapping',
          description: 'UK and Pan-European KOL mapping and engagement. NHS consultant and Royal College member networks. Multi-country medical association partnerships and hospital provider panels.',
        },
        {
          title: 'Geographic Coverage: UK ‚Ä¢ Europe ‚Ä¢ MENA',
          description: 'UK: NHS England, Scotland, Wales, Northern Ireland; London teaching hospitals; NICE, MHRA stakeholder research. Europe: Germany (G-BA, IQWiG), France (HAS, CEPS), Spain, Italy, Netherlands, Belgium, Switzerland. MENA: UAE (DHA, HAAD), Saudi Arabia (Vision 2030), Egypt, Kuwait, Qatar.',
        },
        {
          title: 'Methodology & Compliance',
          description: 'MHRA and EMA regulatory alignment. GDPR-compliant data collection. NHS Research Ethics Committee (REC) standards. Multi-lingual survey deployment (English, German, French, Spanish, Italian, Arabic). Secure data encryption and HEOR analysis.',
        },
      ],
    },
    insights: {
      title: 'Latest Insights',
      subtitle: 'Thought leadership and research perspectives from our global team',
      readMore: 'Read Article',
      items: [
        {
          category: 'Market Access',
          title: 'The Future of Value-Based Healthcare Agreements in Europe',
          excerpt: 'How innovative contracting models are reshaping pharmaceutical pricing and access strategies across major European markets.',
          date: '2024 Q4 Report',
        },
        {
          category: 'Digital Health',
          title: 'AI-Driven Drug Discovery: Market Implications',
          excerpt: 'Analyzing the competitive landscape shift as artificial intelligence transforms pharmaceutical R&D and time-to-market.',
          date: 'Strategic Brief',
        },
        {
          category: 'Oncology',
          title: 'Precision Medicine Market Dynamics 2025',
          excerpt: 'Comprehensive analysis of biomarker-driven therapies and the evolving oncology treatment paradigm.',
          date: 'Industry Analysis',
        },
      ],
    },
    blog: {
      title: 'Latest Insights',
      subtitle: 'Thought leadership and research perspectives from our global team',
      readMore: 'Read Article',
      readMoreArticles: 'Read more articles',
      filterAllTopics: 'All topics',
      filterAllCountries: 'All countries',
      filterByTopic: 'Topic',
      filterByCountry: 'Country',
      items: [
        { category: 'Market Access', country: 'Europe', title: 'The Future of Value-Based Healthcare Agreements in Europe', excerpt: 'How innovative contracting models are reshaping pharmaceutical pricing and access strategies across major European markets.', date: '2024 Q4 Report' },
        { category: 'Digital Health', country: 'USA', title: 'AI-Driven Drug Discovery: Market Implications', excerpt: 'Analyzing the competitive landscape shift as artificial intelligence transforms pharmaceutical R&D and time-to-market.', date: 'Strategic Brief' },
        { category: 'Oncology', country: 'UK', title: 'Precision Medicine Market Dynamics 2025', excerpt: 'Comprehensive analysis of biomarker-driven therapies and the evolving oncology treatment paradigm.', date: 'Industry Analysis' },
      ],
    },
    stats: {
      title: 'Global Impact',
      items: [
        { value: '50+', label: 'Countries Covered' },
        { value: '10+', label: 'Pharma Clients' },
        { value: '120+', label: 'Projects Delivered' },
        { value: '15+', label: 'Years Experience' },
      ],
    },
    testimonials: {
      title: 'Client Perspectives',
      subtitle: 'Trusted by leading pharmaceutical and biotech companies worldwide',
      items: [
        { quote: 'BioNixus transformed our market access strategy with insights that were both rigorous and actionable. Their perspective was invaluable.', author: 'Dr. Sarah Mitchell', role: 'VP Market Access', company: 'Global Pharma Inc.' },
        { quote: 'The depth of competitive intelligence and speed of delivery exceeded our expectations. A true strategic partner.', author: 'Michael Chen', role: 'Chief Strategy Officer', company: 'BioTech Company' },
        { quote: 'Their KOL mapping and patient journey research directly influenced our launch success in three major European markets.', author: 'Dr. Elena Rodriguez', role: 'Commercial Director', company: 'Leading Pharma Company' },
      ],
    },
    contact: {
      title: "Let's Connect",
      subtitle: 'Ready to transform your healthcare market strategy? Our team of experts is here to help.',
      cta: 'Schedule a Consultation',
      ctaSecondary: 'Explore Our Services',
      email: 'admin@bionixus.com',
      headquarters: 'Wyoming, USA',
      emailLabel: 'Email',
      headquartersLabel: 'Headquarters',
      phoneLabel: 'Phone',
      formTitle: 'Request a Proposal',
      firstName: 'First Name',
      lastName: 'Last Name',
      workEmail: 'Work Email',
      company: 'Company',
      message: 'Message',
      submitButton: 'Submit',
      firstNamePlaceholder: 'John',
      lastNamePlaceholder: 'Smith',
      workEmailPlaceholder: 'john@company.com',
      companyPlaceholder: 'Your Company',
      messagePlaceholder: 'Tell us about your research needs...',
      successTitle: 'Thank You!',
      successBody: 'Your inquiry has been successfully submitted. Our team will get back to you shortly.',
      successCaseStudiesText: 'case studies',
      successMethodologyText: 'methodology',
      successFollowUpIntro: 'Explore our ',
      successFollowUpBetween: ' or ',
      successFollowUpEnd: ' sections in the meantime.',
      validation: {
        firstName: 'Please enter your first name',
        lastName: 'Please enter your last name',
        workEmail: 'Please enter a valid work email',
        company: 'Please enter your company name',
        message: 'Please describe how we can help you',
        privacy: 'Please accept the privacy policy',
        emailFormat: 'Please enter a valid email address',
        success: 'Your inquiry was successfully submitted!',
        error: 'Something went wrong. Please try again or contact us by email.',
      },
    },
    localePrompt: {
      title: 'You are opening from {region}.',
      question: 'Do you want to switch to {language}?',
      yes: 'Yes',
      no: 'No',
    },
    footer: {
      tagline: 'Healthcare Market Research | Pharma Insights Europe & MENA. Delivering evidence-based insights to pharmaceutical and biotech leaders worldwide.',
      companyHeading: 'Company',
      about: 'About',
      services: 'Services',
      insights: 'Insights',
      careers: 'Careers',
      clientsPortal: "Clients' Portal",
      caseStudies: 'Case Studies',
      contactHeading: 'Contact',
      locationUs: 'Wyoming, USA',
      locationUk: 'London, UK',
      copyright: '¬© 2026 BioNixus. All rights reserved.',
      privacy: 'Privacy Policy',
      terms: 'Terms of Service',
    },
    cookieConsent: {
      message: 'We use cookies to improve your experience and analyse site traffic. By clicking Accept you agree to our use of cookies and our Privacy Policy.',
      accept: 'Accept',
      decline: 'Decline',
      privacyLink: 'Privacy Policy',
    },
  },
  de: {
    nav: {
      services: 'Leistungen',
      insights: 'Erkenntnisse',
      about: '√úber uns',
      contact: 'Kontakt',
    },
    hero: {
      tagline: 'EMEA Gesundheitsmarktforschung',
      title: 'EMEA Gesundheitsmarktforschung f√ºr pharmazeutische Exzellenz',
      subtitle: 'Verwandeln Sie √Ñrzte- und Krankenhaus-Erkenntnisse in strategische Intelligenz in UK-, Europa- und MENA-M√§rkten',
      valueProposition: 'Wir liefern umfassende quantitative und qualitative Marktforschung, die klinische Daten in umsetzbare pharmazeutische Intelligence verwandelt. Unsere spezialisierte Methodik erfasst authentische √Ñrzteperspektiven aus NHS und privaten Gesundheitssystemen, Krankenhaustrends und Patienteneinblicken in UK, Europa und MENA.',
      serviceHighlights: ['UK NHS & Private Healthcare Research', 'Pan-europ√§ische √Ñrztebefragungen', 'Qualitative Meinungsf√ºhrer-Interviews (KOL)', 'Mehrl√§nder-Datenanalyse', 'UK ‚Ä¢ Europa ‚Ä¢ MENA Abdeckung'],
      cta: 'UK-Forschungsangebot anfordern',
      ctaSecondary: 'Europ√§ische Fallstudien ansehen',
      trustBar: 'Vertrauensw√ºrdig in',
      trustCountries: 'UK ‚Ä¢ Deutschland ‚Ä¢ Frankreich ‚Ä¢ Spanien ‚Ä¢ Italien ‚Ä¢ UAE ‚Ä¢ Saudi-Arabien ‚Ä¢ √Ñgypten ‚Ä¢ Kuwait ‚Ä¢ Katar',
      complianceBadges: ['MHRA Compliant', 'EMA Aligned', 'GDPR Compliant', 'SFDA Compliant', 'ICH-GCP'],
    },
    services: {
      title: 'Umfassende Gesundheitsmarktforschungsdienstleistungen f√ºr UK & europ√§ische Pharmaunternehmen',
      subtitle: 'Quantitative und qualitative Erkenntnisse von √Ñrzten und Krankenh√§usern in UK, Europa & MENA',
      items: [
        {
          title: 'Quantitative Gesundheitsforschung & √Ñrztebefragungen',
          description: 'Gro√ü angelegte statistische Erkenntnisse von √Ñrzten und Gesundheitsfachkr√§ften in UK, Europa und MENA. Leistungen: NHS- und private Anbieterforschung, Krankenhauspr√§ferenzstudien, Verschreibungsverfolgung, Gesundheitstechnologiebewertungs-Entscheider-Erkenntnisse, Kostentr√§geranalyse, Mehrl√§nder-Umfragen (UAE, Saudi-Arabien, √Ñgypten, Kuwait, Katar). Lieferungen: Statistische Berichte, Marktgr√∂√üensch√§tzung, Pfadanalyse, Prognosen, Segmentierung, vergleichende Erkenntnisse.',
        },
        {
          title: 'Qualitative pharmazeutische Forschung & Experten-Erkenntnisse',
          description: 'Tiefgehende qualitative Forschung zu klinischen Perspektiven und ungedeckten medizinischen Bed√ºrfnissen in UK, Europa und MENA. Leistungen: NHS-Berater/GP-Interviews, NICE-Ausschuss-Engagement, pan-europ√§isches KOL-Mapping, l√§nder√ºbergreifende Fokusgruppen, Behandlungspfad-Analyse, Golf-Gesundheitswesen-Erkenntnisse. Lieferungen: Thematische Analyse, Konsenszusammenfassungen, Marktzugangs-Empfehlungen, KOL-Strategien.',
        },
        {
          title: 'Marktzugang & Gesundheitstechnologiebewertungs-Strategie',
          description: 'NICE-, G-BA-, HAS- und Gesundheitstechnologiebewertungs-Anforderungsintegration. Evidenzbasierte Preisstrategien und Kostentr√§ger-Engagement-Frameworks f√ºr UK und europ√§ische M√§rkte. Kosten-Nutzen-Analyse f√ºr Gesundheitstechnologiebewertungs-Einreichungen.',
        },
        {
          title: 'KOL & Stakeholder-Mapping',
          description: 'UK- und pan-europ√§isches KOL-Mapping und Engagement. NHS-Berater- und Royal College-Mitglieder-Netzwerke. Mehrl√§nder-√Ñrzteverbands-Partnerschaften und Krankenhaus-Anbieter-Panels.',
        },
        {
          title: 'Geografische Abdeckung: Europa ‚Ä¢ MENA',
          description: 'UK: NHS England, Schottland, Wales, Nordirland; Londoner Lehrkrankenh√§user; NICE, MHRA Stakeholder-Forschung. Europa: Deutschland (G-BA, IQWiG), Frankreich (HAS, CEPS), Spanien, Italien, Niederlande, Belgien, Schweiz. MENA: UAE (DHA, HAAD), Saudi-Arabien (Vision 2030), √Ñgypten, Kuwait, Katar.',
        },
        {
          title: 'Methodik & Compliance',
          description: 'MHRA- und EMA-Regulierungskonformit√§t. DSGVO-konforme Datenerhebung. NHS Research Ethics Committee (REC) Standards. Mehrsprachige Umfragebereitstellung (Englisch, Deutsch, Franz√∂sisch, Spanisch, Italienisch, Arabisch). Sichere Datenverschl√ºsselung und Gesundheits√∂konomie und Versorgungsforschung (HEOR)-Analyse.',
        },
      ],
    },
    geographicCoverageDe: {
      title: 'Geografische Abdeckung: Europa ‚Ä¢ MENA',
      regions: [
        { name: 'Europa - Pan-europ√§isches Forschungsnetzwerk', countries: [{ name: 'Deutschland', items: ['G-BA und IQWiG Stakeholder-Forschung', 'Krankenhaus und ambulante Versorgung'] }, { name: 'Frankreich', items: ['HAS und CEPS Entscheider-Erkenntnisse', '√ñffentliche und private Krankenh√§user'] }, { name: 'Weitere M√§rkte', items: ['UK, Spanien, Italien, Niederlande, Belgien, Schweiz', 'Regionale Gesundheitssysteme und Fachversorgung'] }] },
        { name: 'MENA - Strategische Markterweiterung', countries: [{ name: 'UAE', items: ['DHA- und HAAD-regulierte Einrichtungen', 'Dubai Healthcare City'] }, { name: 'Saudi-Arabien', items: ['MOH und Vision 2030 Gesundheitswesen-Transformation'] }, { name: 'Weitere M√§rkte', items: ['√Ñgypten, Kuwait, Katar', '√ñffentliche und private Gesundheitsnetzwerke'] }] },
      ],
    },
    methodologyDe: {
      title: 'Methodik & Compliance',
      intro: 'Unsere Forschung entspricht den h√∂chsten Standards der regulatorischen Compliance und Datensicherheit.',
      steps: [
        { title: 'Regulatorische Ausrichtung', description: 'MHRA- und EMA-Regulierungskonformit√§t. NHS Research Ethics Committee (REC) Standards. DSGVO-konforme Datenerhebungsprotokolle. ICH-GCP-Richtlinien f√ºr klinische Forschung.' },
        { title: 'Datenerhebung & Qualit√§t', description: 'Mehrsprachige Umfragebereitstellung (Englisch, Deutsch, Franz√∂sisch, Spanisch, Italienisch, Arabisch). Echtzeit-Datenvalidierung und Qualit√§tspr√ºfungen. √Ñrzteidentit√§tsverifizierungsprotokolle. Sichere Datenverschl√ºsselung und Speicherung.' },
        { title: 'Erweiterte Analytik', description: 'Statistische Modellierung und pr√§diktive Analytik. HEOR. Kosten-Nutzen-Analyse f√ºr Gesundheitstechnologiebewertungs-Einreichungen. L√§nder√ºbergreifende vergleichende Analyse.' },
      ],
    },
    therapeuticAreasDe: {
      title: 'Therapeutische Schwerpunkte',
      areas: [
        { name: 'Onkologie', description: 'Behandlungspfade, KOL-Mapping, Biologika-Adoption' },
        { name: 'Endokrinologie', description: 'Diabetes, Adipositas, Schilddr√ºse' },
        { name: 'Seltene Erkrankungen', description: 'Zugangsstrategien, Patient Journey' },
      ],
    },
    insights: {
      title: 'Aktuelle Erkenntnisse',
      subtitle: 'Thought Leadership und Forschungsperspektiven von unserem globalen Team',
      readMore: 'Artikel lesen',
      items: [
        {
          category: 'Marktzugang',
          title: 'Die Zukunft wertbasierter Gesundheitsvereinbarungen in Europa',
          excerpt: 'Wie innovative Vertragsmodelle pharmazeutische Preis- und Zugangsstrategien in gro√üen europ√§ischen M√§rkten umgestalten.',
          date: '2024 Q4 Bericht',
        },
        {
          category: 'Digitale Gesundheit',
          title: 'KI-gesteuerte Arzneimittelentdeckung: Marktimplikationen',
          excerpt: 'Analyse der Wettbewerbslandschaftsverschiebung, w√§hrend k√ºnstliche Intelligenz pharmazeutische F&E transformiert.',
          date: 'Strategische Kurzanalyse',
        },
        {
          category: 'Onkologie',
          title: 'Pr√§zisionsmedizin Marktdynamik 2025',
          excerpt: 'Umfassende Analyse von Biomarker-gesteuerten Therapien und dem sich entwickelnden Onkologie-Behandlungsparadigma.',
          date: 'Branchenanalyse',
        },
      ],
    },
    blog: {
      title: 'Aktuelle Erkenntnisse',
      subtitle: 'Thought Leadership und Forschungsperspektiven von unserem globalen Team',
      readMore: 'Artikel lesen',
      readMoreArticles: 'Weitere Artikel lesen',
      filterAllTopics: 'Alle Themen',
      filterAllCountries: 'Alle L√§nder',
      filterByTopic: 'Thema',
      filterByCountry: 'Land',
      items: [
        { category: 'Marktzugang', country: 'Europa', title: 'Die Zukunft wertbasierter Gesundheitsvereinbarungen in Europa', excerpt: 'Wie innovative Vertragsmodelle pharmazeutische Preis- und Zugangsstrategien in gro√üen europ√§ischen M√§rkten umgestalten.', date: '2024 Q4 Bericht' },
        { category: 'Digitale Gesundheit', country: 'USA', title: 'KI-gesteuerte Arzneimittelentdeckung: Marktimplikationen', excerpt: 'Analyse der Wettbewerbslandschaftsverschiebung, w√§hrend k√ºnstliche Intelligenz pharmazeutische F&E transformiert.', date: 'Strategische Kurzanalyse' },
        { category: 'Onkologie', country: 'UK', title: 'Pr√§zisionsmedizin Marktdynamik 2025', excerpt: 'Umfassende Analyse von Biomarker-gesteuerten Therapien und dem sich entwickelnden Onkologie-Behandlungsparadigma.', date: 'Branchenanalyse' },
      ],
    },
    stats: {
      title: 'Globale Wirkung',
      items: [
        { value: '50+', label: 'Abgedeckte L√§nder' },
        { value: '10+', label: 'Pharma-Kunden' },
        { value: '120+', label: 'Gelieferte Projekte' },
        { value: '15+', label: 'Jahre Erfahrung' },
      ],
    },
    testimonials: {
      title: 'Kundenperspektiven',
      subtitle: 'Vertraut von f√ºhrenden Pharma- und Biotech-Unternehmen weltweit',
      items: [
        { quote: 'BioNixus hat unsere Marktzugangsstrategie mit Erkenntnissen transformiert, die sowohl rigoros als auch umsetzbar waren. Ihre Perspektive war von unsch√§tzbarem Wert.', author: 'Dr. Sarah Mitchell', role: 'VP Marktzugang', company: 'Global Pharma Inc.' },
        { quote: 'Die Tiefe der Wettbewerbsintelligenz und die Liefergeschwindigkeit √ºbertrafen unsere Erwartungen. Ein wahrer strategischer Partner.', author: 'Michael Chen', role: 'Chief Strategy Officer', company: 'BioTech Company' },
        { quote: 'Ihr Meinungsf√ºhrer-Mapping (KOL) und Patient-Journey-Forschung beeinflussten unseren Markteintrittserfolg in drei europ√§ischen Kernm√§rkten direkt.', author: 'Dr. Elena Rodriguez', role: 'Commercial Director', company: 'Leading Pharma Company' },
      ],
    },
    contact: {
      title: 'Lassen Sie uns verbinden',
      subtitle: 'Bereit, Ihre Gesundheitsmarktstrategie zu transformieren? Unser Expertenteam steht Ihnen zur Verf√ºgung.',
      cta: 'Beratung vereinbaren',
      ctaSecondary: 'Unsere Leistungen erkunden',
      email: 'admin@bionixus.com',
      headquarters: 'Wyoming, USA',
      emailLabel: 'E-Mail',
      headquartersLabel: 'Hauptsitz',
      phoneLabel: 'Telefon',
      formTitle: 'Angebot anfordern',
      firstName: 'Vorname',
      lastName: 'Nachname',
      workEmail: 'Gesch√§ftliche E-Mail',
      company: 'Unternehmen',
      message: 'Nachricht',
      submitButton: 'Absenden',
      firstNamePlaceholder: 'Max',
      lastNamePlaceholder: 'Mustermann',
      workEmailPlaceholder: 'max@firma.de',
      companyPlaceholder: 'Ihr Unternehmen',
      messagePlaceholder: 'Beschreiben Sie Ihren Forschungsbedarf...',
      successTitle: 'Vielen Dank!',
      successBody: 'Ihre Anfrage wurde erfolgreich √ºbermittelt. Unser Team wird sich in K√ºrze bei Ihnen melden.',
      successCaseStudiesText: 'Fallstudien',
      successMethodologyText: 'Methodik',
      successFollowUpIntro: 'Entdecken Sie unsere ',
      successFollowUpBetween: ' oder ',
      successFollowUpEnd: ' in der Zwischenzeit.',
      validation: {
        firstName: 'Bitte geben Sie Ihren Vornamen ein',
        lastName: 'Bitte geben Sie Ihren Nachnamen ein',
        workEmail: 'Bitte geben Sie eine g√ºltige Gesch√§fts-E-Mail ein',
        company: 'Bitte geben Sie Ihren Firmennamen ein',
        message: 'Bitte beschreiben Sie, wie wir Ihnen helfen k√∂nnen',
        privacy: 'Bitte akzeptieren Sie die Datenschutzerkl√§rung',
        emailFormat: 'Bitte geben Sie eine g√ºltige E-Mail-Adresse ein',
        success: 'Ihre Anfrage wurde erfolgreich √ºbermittelt!',
        error: 'Etwas ist schief gelaufen. Bitte versuchen Sie es erneut oder kontaktieren Sie uns per E-Mail.',
      },
    },
    localePrompt: {
      title: 'Sie √∂ffnen von {region}.',
      question: 'M√∂chten Sie zu {language} wechseln?',
      yes: 'Ja',
      no: 'Nein',
    },
    footer: {
      tagline: 'Gesundheitsmarktforschung | Pharma-Insights Europa & MENA. Evidenzbasierte Erkenntnisse f√ºr Pharma- und Biotech-F√ºhrungskr√§fte weltweit.',
      companyHeading: 'Unternehmen',
      about: '√úber uns',
      services: 'Dienstleistungen',
      insights: 'Insights',
      careers: 'Karriere',
      clientsPortal: 'Kundenportal',
      caseStudies: 'Fallstudien',
      contactHeading: 'Kontakt',
      locationUs: 'Wyoming, USA',
      locationUk: 'London, UK',
      copyright: '¬© 2026 BioNixus. Alle Rechte vorbehalten.',
      privacy: 'Datenschutzerkl√§rung',
      terms: 'Nutzungsbedingungen',
    },
    cookieConsent: {
      message: 'Wir verwenden Cookies, um Ihre Erfahrung zu verbessern und den Website-Traffic zu analysieren. Mit Klick auf Akzeptieren stimmen Sie unserer Cookie-Nutzung und der Datenschutzerkl√§rung zu.',
      accept: 'Akzeptieren',
      decline: 'Ablehnen',
      privacyLink: 'Datenschutz',
    },
  },
  fr: {
    nav: {
      services: 'Services',
      insights: 'Perspectives',
      about: '√Ä propos',
      contact: 'Contact',
    },
    hero: {
      tagline: '√âtudes de March√© Sant√© EMEA',
      title: '√âtudes de March√© Sant√© EMEA pour l\'Excellence Pharmaceutique',
      subtitle: 'Transformez les insights m√©decins et h√¥pitaux en intelligence strat√©gique sur les march√©s UK, Europe et MENA',
      valueProposition: 'Nous fournissons des √©tudes de march√© quantitatives et qualitatives compl√®tes qui transforment les donn√©es cliniques en intelligence pharmaceutique exploitable. Notre m√©thodologie sp√©cialis√©e capture les perspectives authentiques des m√©decins du NHS et du priv√©, les tendances hospitali√®res et les insights patients en UK, Europe et MENA.',
      serviceHighlights: ['Recherche NHS & Priv√© UK', 'Enqu√™tes m√©decins pan-europ√©ennes', 'Interviews Leaders d\'Opinion Cl√©s (KOL) qualitatives', 'Analyses multi-pays', 'Couverture UK ‚Ä¢ Europe ‚Ä¢ MENA'],
      cta: 'Demander une proposition UK',
      ctaSecondary: 'Voir les √©tudes de cas europ√©ennes',
      trustBar: 'Partenaire de confiance des laboratoires pharmaceutiques en',
      trustCountries: 'UK ‚Ä¢ Allemagne ‚Ä¢ France ‚Ä¢ Espagne ‚Ä¢ Italie ‚Ä¢ EAU ‚Ä¢ Arabie Saoudite ‚Ä¢ √âgypte ‚Ä¢ Kowe√Øt ‚Ä¢ Qatar',
      complianceBadges: ['MHRA Compliant', 'EMA Aligned', 'GDPR Compliant', 'SFDA Compliant', 'ICH-GCP'],
    },
    services: {
      title: '√âtudes de March√© Sant√© Compl√®tes pour les Entreprises Pharmaceutiques UK & Europ√©ennes',
      subtitle: 'Insights quantitatifs et qualitatifs des m√©decins et h√¥pitaux en UK, Europe & MENA',
      items: [
        {
          title: 'Recherche Quantitative & Enqu√™tes M√©decins',
          description: 'Insights statistiques √† grande √©chelle des m√©decins et professionnels de sant√© en UK, Europe et MENA. Services: recherche NHS et secteur priv√©, √©tudes de pr√©f√©rence hospitali√®re, suivi des prescriptions, insights d√©cideurs √âvaluation des Technologies de Sant√© (ETS), analyse payeurs, enqu√™tes multi-pays (EAU, Arabie Saoudite, √âgypte, Kowe√Øt, Qatar). Livrables: rapports statistiques, sizing march√©, analyse des parcours, pr√©visions, segmentation, insights comparatifs.',
        },
        {
          title: 'Recherche Qualitative Pharmaceutique & Insights Experts',
          description: 'Recherche qualitative approfondie capturant les perspectives cliniques et besoins m√©dicaux non couverts en UK, Europe et MENA. Services: interviews consultants NHS/GP, engagement comit√©s NICE, mapping KOL pan-europ√©en, focus groups multi-pays, analyse des parcours de soins, insights syst√®me sant√© du Golfe. Livrables: analyse th√©matique, synth√®ses consensus, recommandations acc√®s march√©, strat√©gies KOL.',
        },
        {
          title: 'Acc√®s au March√© & Strat√©gie √âvaluation des Technologies de Sant√© (ETS)',
          description: 'Int√©gration des exigences NICE, G-BA, HAS et √âvaluation des Technologies de Sant√© (ETS). Strat√©gies de prix fond√©es sur les preuves et cadres d\'engagement payeurs pour UK et Europe. Mod√©lisation paysage remboursement et analyse co√ªt-efficacit√© pour dossiers ETS.',
        },
        {
          title: 'Mapping KOL & Parties Prenantes',
          description: 'Mapping et engagement KOL UK et pan-europ√©en. R√©seaux consultants NHS et membres Royal College. Partenariats associations m√©dicales multi-pays et panels fournisseurs hospitaliers.',
        },
        {
          title: 'Couverture G√©ographique: Europe ‚Ä¢ MENA',
          description: 'UK: NHS England, √âcosse, Pays de Galles, Irlande du Nord; h√¥pitaux universitaires London; recherche parties prenantes NICE, MHRA. Europe: Allemagne (G-BA, IQWiG), France (HAS, CEPS), Espagne, Italie, Pays-Bas, Belgique, Suisse. MENA: EAU (DHA, HAAD), Arabie Saoudite (Vision 2030), √âgypte, Kowe√Øt, Qatar.',
        },
        {
          title: 'M√©thodologie & Conformit√©',
          description: 'Alignement r√©glementaire MHRA et EMA. Collecte de donn√©es conforme RGPD. Normes NHS Research Ethics Committee (REC). D√©ploiement d\'enqu√™tes multilingues (anglais, allemand, fran√ßais, espagnol, italien, arabe). Chiffrement et analyse √âconomie de la Sant√© et Recherche sur les R√©sultats (HEOR).',
        },
      ],
    },
    geographicCoverageFr: {
      title: 'Couverture G√©ographique: Europe ‚Ä¢ MENA',
      regions: [
        { name: 'Europe - R√©seau de Recherche Pan-europ√©en', countries: [{ name: 'Allemagne', items: ['Recherche parties prenantes G-BA et IQWiG', 'Soins hospitaliers et ambulatoires'] }, { name: 'France', items: ['Insights d√©cideurs HAS et CEPS', 'H√¥pitaux publics et priv√©s'] }, { name: 'Autres march√©s', items: ['UK, Espagne, Italie, Pays-Bas, Belgique, Suisse', 'Syst√®mes de sant√© r√©gionaux et soins sp√©cialis√©s'] }] },
        { name: 'MENA - Expansion Strat√©gique', countries: [{ name: 'EAU', items: ['√âtablissements r√©glement√©s DHA et HAAD', 'Dubai Healthcare City'] }, { name: 'Arabie Saoudite', items: ['Transformation sant√© MOH et Vision 2030'] }, { name: 'Autres march√©s', items: ['√âgypte, Kowe√Øt, Qatar', 'R√©seaux de sant√© publics et priv√©s'] }] },
      ],
    },
    methodologyFr: {
      title: 'M√©thodologie & Conformit√©',
      intro: 'Notre recherche respecte les plus hauts standards de conformit√© r√©glementaire et de s√©curit√© des donn√©es.',
      steps: [
        { title: 'Alignement R√©glementaire', description: 'Conformit√© MHRA et EMA. Normes NHS Research Ethics Committee (REC). Protocoles de collecte conformes RGPD. Lignes directrices ICH-GCP pour la recherche clinique.' },
        { title: 'Collecte de Donn√©es & Qualit√©', description: 'D√©ploiement d\'enqu√™tes multilingues (fran√ßais, anglais, allemand, espagnol, italien, arabe). Validation et contr√¥les qualit√© en temps r√©el. Protocoles de v√©rification d\'identit√© des m√©decins. Chiffrement et stockage s√©curis√©s.' },
        { title: 'Analytique Avanc√©e', description: 'Mod√©lisation statistique et analytique pr√©dictive. HEOR. Analyse co√ªt-efficacit√© pour dossiers √âvaluation des Technologies de Sant√© (ETS). Analyse comparative transnationale.' },
      ],
    },
    therapeuticAreasFr: {
      title: 'Domaines Th√©rapeutiques',
      areas: [
        { name: 'Oncologie', description: 'Parcours de soins, mapping KOL, adoption bioth√©rapies' },
        { name: 'Endocrinologie', description: 'Diab√®te, ob√©sit√©, thyro√Øde' },
        { name: 'Maladies Rares', description: 'Strat√©gies d\'acc√®s, parcours patient' },
      ],
    },
    insights: {
      title: 'Derni√®res Perspectives',
      subtitle: 'Leadership √©clair√© et perspectives de recherche de notre √©quipe mondiale',
      readMore: 'Lire l\'article',
      items: [
        {
          category: 'Acc√®s au March√©',
          title: 'L\'Avenir des Accords de Sant√© Bas√©s sur la Valeur en Europe',
          excerpt: 'Comment les mod√®les contractuels innovants remod√®lent les strat√©gies de prix et d\'acc√®s pharmaceutiques.',
          date: 'Rapport T4 2024',
        },
        {
          category: 'Sant√© Num√©rique',
          title: 'D√©couverte de M√©dicaments par l\'IA: Implications March√©',
          excerpt: 'Analyse du changement de paysage concurrentiel alors que l\'IA transforme la R&D pharmaceutique.',
          date: 'Note Strat√©gique',
        },
        {
          category: 'Oncologie',
          title: 'Dynamique du March√© de la M√©decine de Pr√©cision 2025',
          excerpt: 'Analyse compl√®te des th√©rapies guid√©es par biomarqueurs et du paradigme de traitement oncologique.',
          date: 'Analyse Sectorielle',
        },
      ],
    },
    blog: {
      title: 'Derni√®res Perspectives',
      subtitle: 'Leadership √©clair√© et perspectives de recherche de notre √©quipe mondiale',
      readMore: 'Lire l\'article',
      readMoreArticles: 'Lire plus d\'articles',
      filterAllTopics: 'Tous les th√®mes',
      filterAllCountries: 'Tous les pays',
      filterByTopic: 'Th√®me',
      filterByCountry: 'Pays',
      items: [
        { category: 'Acc√®s au March√©', country: 'Europe', title: 'L\'Avenir des Accords de Sant√© Bas√©s sur la Valeur en Europe', excerpt: 'Comment les mod√®les contractuels innovants remod√®lent les strat√©gies de prix et d\'acc√®s pharmaceutiques.', date: 'Rapport T4 2024' },
        { category: 'Sant√© Num√©rique', country: 'USA', title: 'D√©couverte de M√©dicaments par l\'IA: Implications March√©', excerpt: 'Analyse du changement de paysage concurrentiel alors que l\'IA transforme la R&D pharmaceutique.', date: 'Note Strat√©gique' },
        { category: 'Oncologie', country: 'Royaume-Uni', title: 'Dynamique du March√© de la M√©decine de Pr√©cision 2025', excerpt: 'Analyse compl√®te des th√©rapies guid√©es par biomarqueurs et du paradigme de traitement oncologique.', date: 'Analyse Sectorielle' },
      ],
    },
    stats: {
      title: 'Impact Mondial',
      items: [
        { value: '50+', label: 'Pays Couverts' },
        { value: '10+', label: 'Clients Pharma' },
        { value: '120+', label: 'Projets Livr√©s' },
        { value: '15+', label: 'Ans d\'Exp√©rience' },
      ],
    },
    testimonials: {
      title: 'Perspectives Clients',
      subtitle: 'Approuv√© par les principales entreprises pharmaceutiques et biotechnologiques mondiales',
      items: [
        { quote: 'BioNixus a transform√© notre strat√©gie d\'acc√®s au march√© avec des insights √† la fois rigoureux et exploitables. Leur perspective a √©t√© inestimable.', author: 'Dr. Sarah Mitchell', role: 'VP Acc√®s au March√©', company: 'Global Pharma Inc.' },
        { quote: 'La profondeur de l\'intelligence concurrentielle et la rapidit√© de livraison ont d√©pass√© nos attentes. Un v√©ritable partenaire strat√©gique.', author: 'Michael Chen', role: 'Chief Strategy Officer', company: 'BioTech Company' },
        { quote: 'Leur cartographie des Leaders d\'Opinion Cl√©s (KOL) et la recherche du parcours patient ont directement influenc√© notre succ√®s de lancement sur trois march√©s europ√©ens majeurs.', author: 'Dr. Elena Rodriguez', role: 'Directeur Commercial', company: 'Leading Pharma Company' },
      ],
    },
    contact: {
      title: 'Connectons-nous',
      subtitle: 'Pr√™t √† transformer votre strat√©gie de march√© sant√©? Notre √©quipe d\'experts est l√† pour vous aider.',
      cta: 'Demander une Proposition',
      ctaSecondary: 'Explorer nos Services',
      email: 'admin@bionixus.com',
      headquarters: 'Wyoming, USA',
      emailLabel: 'E-mail',
      headquartersLabel: 'Si√®ge',
      phoneLabel: 'T√©l√©phone',
      formTitle: 'Demander une proposition',
      firstName: 'Pr√©nom',
      lastName: 'Nom',
      workEmail: 'E-mail professionnel',
      company: 'Entreprise',
      message: 'Message',
      submitButton: 'Envoyer',
      firstNamePlaceholder: 'Jean',
      lastNamePlaceholder: 'Dupont',
      workEmailPlaceholder: 'jean@entreprise.com',
      companyPlaceholder: 'Votre entreprise',
      messagePlaceholder: 'D√©crivez vos besoins en recherche...',
      successTitle: 'Merci!',
      successBody: 'Votre demande a √©t√© soumise avec succ√®s. Notre √©quipe vous contactera prochainement.',
      successCaseStudiesText: '√©tudes de cas',
      successMethodologyText: 'm√©thodologie',
      successFollowUpIntro: 'D√©couvrez nos ',
      successFollowUpBetween: ' ou ',
      successFollowUpEnd: ' en attendant.',
      validation: {
        firstName: 'Veuillez entrer votre pr√©nom',
        lastName: 'Veuillez entrer votre nom',
        workEmail: 'Veuillez entrer un e-mail professionnel valide',
        company: 'Veuillez entrer le nom de votre entreprise',
        message: 'Veuillez d√©crire comment nous pouvons vous aider',
        privacy: 'Veuillez accepter la politique de confidentialit√©',
        emailFormat: 'Veuillez entrer une adresse e-mail valide',
        success: 'Votre demande a √©t√© soumise avec succ√®s!',
        error: 'Une erreur s\'est produite. Veuillez r√©essayer ou nous contacter par e-mail.',
      },
    },
    localePrompt: {
      title: 'Vous ouvrez depuis {region}.',
      question: 'Voulez-vous passer √† {language} ?',
      yes: 'Oui',
      no: 'Non',
    },
    footer: {
      tagline: '√âtudes de March√© Sant√© | Insights Pharma Europe & MENA. Des insights fond√©s sur des preuves pour les leaders pharmaceutiques et biotech du monde entier.',
      companyHeading: 'Entreprise',
      about: '√Ä propos',
      services: 'Services',
      insights: 'Insights',
      careers: 'Carri√®res',
      clientsPortal: 'Portail Client',
      caseStudies: '√âtudes de Cas',
      contactHeading: 'Contact',
      locationUs: 'Wyoming, √âtats-Unis',
      locationUk: 'Londres, Royaume-Uni',
      copyright: '¬© 2026 BioNixus. Tous droits r√©serv√©s.',
      privacy: 'Politique de confidentialit√©',
      terms: 'Conditions d\'utilisation',
    },
    cookieConsent: {
      message: 'Nous utilisons des cookies pour am√©liorer votre exp√©rience et analyser le trafic. En cliquant sur Accepter, vous acceptez notre utilisation des cookies et notre Politique de Confidentialit√©.',
      accept: 'Accepter',
      decline: 'Refuser',
      privacyLink: 'Politique de Confidentialit√©',
    },
  },
  es: {
    nav: {
      services: 'Servicios',
      insights: 'Perspectivas',
      about: 'Nosotros',
      contact: 'Contacto',
    },
    hero: {
      tagline: 'Investigaci√≥n de Mercado Sanitario EMEA',
      title: 'Investigaci√≥n de Mercado Sanitario EMEA para la Excelencia Farmac√©utica',
      subtitle: 'Transforme los insights de m√©dicos y hospitales en inteligencia estrat√©gica en mercados UK, Europa y MENA',
      valueProposition: 'Proporcionamos estudios de mercado cuantitativos y cualitativos que transforman datos cl√≠nicos en inteligencia farmac√©utica accionable. Nuestra metodolog√≠a especializada captura perspectivas aut√©nticas de m√©dicos del NHS y sector privado, tendencias hospitalarias e insights de pacientes en UK, Europa y MENA.',
      serviceHighlights: ['Investigaci√≥n NHS y Privado UK', 'Encuestas m√©dicas pan-europeas', 'Entrevistas L√≠deres de Opini√≥n Clave (KOL) cualitativas', 'An√°lisis multi-pa√≠s', 'Cobertura UK ‚Ä¢ Europa ‚Ä¢ MENA'],
      cta: 'Solicitar Propuesta UK',
      ctaSecondary: 'Ver Estudios de Caso Europeos',
      trustBar: 'Socio de confianza de laboratorios farmac√©uticos en',
      trustCountries: 'UK ‚Ä¢ Alemania ‚Ä¢ Francia ‚Ä¢ Espa√±a ‚Ä¢ Italia ‚Ä¢ EAU ‚Ä¢ Arabia Saud√≠ ‚Ä¢ Egipto ‚Ä¢ Kuwait ‚Ä¢ Qatar',
      complianceBadges: ['MHRA Compliant', 'EMA Aligned', 'GDPR Compliant', 'SFDA Compliant', 'ICH-GCP'],
    },
    services: {
      title: 'Servicios Integrales de Investigaci√≥n de Mercado Sanitario para Empresas Farmac√©uticas UK y Europeas',
      subtitle: 'Insights cuantitativos y cualitativos de m√©dicos y hospitales en UK, Europa y MENA',
      items: [
        {
          title: 'Investigaci√≥n Cuantitativa Sanitaria y Encuestas M√©dicas',
          description: 'Insights estad√≠sticos a gran escala de m√©dicos y profesionales sanitarios en UK, Europa y MENA. Servicios: investigaci√≥n NHS y proveedores privados, estudios de preferencia hospitalaria, seguimiento de prescripciones, insights decisores Evaluaci√≥n de Tecnolog√≠as Sanitarias (ETS), an√°lisis pagadores, encuestas multi-pa√≠s (EAU, Arabia Saud√≠, Egipto, Kuwait, Qatar). Entregables: informes estad√≠sticos, sizing de mercado, an√°lisis de rutas, pron√≥sticos, segmentaci√≥n, insights comparativos.',
        },
        {
          title: 'Investigaci√≥n Cualitativa Farmac√©utica e Insights Expertos',
          description: 'Investigaci√≥n cualitativa profunda capturando perspectivas cl√≠nicas y necesidades m√©dicas no cubiertas en UK, Europa y MENA. Servicios: entrevistas consultores NHS/GP, engagement comit√©s NICE, mapeo KOL pan-europeo, grupos focales multi-pa√≠s, an√°lisis de rutas de tratamiento, insights sistema sanitario del Golfe. Entregables: an√°lisis tem√°tico, res√∫menes consenso, recomendaciones acceso mercado, estrategias KOL.',
        },
        {
          title: 'Acceso al Mercado y Estrategia Evaluaci√≥n de Tecnolog√≠as Sanitarias (ETS)',
          description: 'Integraci√≥n requisitos NICE, G-BA, HAS y Evaluaci√≥n de Tecnolog√≠as Sanitarias (ETS). Estrategias de precios basadas en evidencia y marcos de engagement pagadores para UK y Europa. Modelado de paisaje reembolso y an√°lisis coste-efectividad para dossiers ETS.',
        },
        {
          title: 'Mapeo KOL y Stakeholders',
          description: 'Mapeo y engagement KOL UK y pan-europeo. Redes consultores NHS y miembros Royal College. Asociaciones con asociaciones m√©dicas multi-pa√≠s y paneles de proveedores hospitalarios.',
        },
        {
          title: 'Cobertura Geogr√°fica: UK ‚Ä¢ Europa ‚Ä¢ MENA',
          description: 'UK: NHS England, Escocia, Gales, Irlanda del Norte; hospitales universitarios Londres; investigaci√≥n stakeholders NICE, MHRA. Europa: Alemania (G-BA, IQWiG), Francia (HAS, CEPS), Espa√±a, Italia, Pa√≠ses Bajos, B√©lgica, Suiza. MENA: EAU (DHA, HAAD), Arabia Saud√≠ (Visi√≥n 2030), Egipto, Kuwait, Qatar.',
        },
        {
          title: 'Metodolog√≠a y Cumplimiento',
          description: 'Alineamiento regulatorio MHRA y EMA. Recopilaci√≥n de datos conforme RGPD. Est√°ndares NHS Research Ethics Committee (REC). Despliegue de encuestas multiling√ºes (ingl√©s, alem√°n, franc√©s, espa√±ol, italiano, √°rabe). Cifrado seguro y an√°lisis Econom√≠a de la Salud e Investigaci√≥n de Resultados (HEOR).',
        },
      ],
    },
    geographicCoverageEs: {
      title: 'Cobertura Geogr√°fica: Europa ‚Ä¢ MENA',
      regions: [
        { name: 'Europa - Red de Investigaci√≥n Pan-europea', countries: [{ name: 'Alemania', items: ['Investigaci√≥n stakeholders G-BA e IQWiG', 'Atenci√≥n hospitalaria y ambulatoria'] }, { name: 'Francia', items: ['Insights decisores HAS y CEPS', 'Hospitales p√∫blicos y privados'] }, { name: 'Mercados adicionales', items: ['UK, Espa√±a, Italia, Pa√≠ses Bajos, B√©lgica, Suiza', 'Sistemas de salud regionales y atenci√≥n especializada'] }] },
        { name: 'MENA - Expansi√≥n Estrat√©gica', countries: [{ name: 'EAU', items: ['Instalaciones reguladas DHA y HAAD', 'Dubai Healthcare City'] }, { name: 'Arabia Saud√≠', items: ['Transformaci√≥n sanitaria MOH y Visi√≥n 2030'] }, { name: 'Mercados adicionales', items: ['Egipto, Kuwait, Qatar', 'Redes sanitarias p√∫blicas y privadas'] }] },
      ],
    },
    methodologyEs: {
      title: 'Metodolog√≠a y Cumplimiento',
      intro: 'Nuestra investigaci√≥n cumple los m√°s altos est√°ndares de cumplimiento regulatorio y seguridad de datos.',
      steps: [
        { title: 'Alineamiento Regulatorio', description: 'Cumplimiento MHRA y EMA. Est√°ndares NHS Research Ethics Committee (REC). Protocolos de recopilaci√≥n conforme RGPD. Directrices ICH-GCP para investigaci√≥n cl√≠nica.' },
        { title: 'Recopilaci√≥n de Datos y Calidad', description: 'Despliegue de encuestas multiling√ºes (espa√±ol, ingl√©s, alem√°n, franc√©s, italiano, √°rabe). Validaci√≥n y controles de calidad en tiempo real. Protocolos de verificaci√≥n de identidad de m√©dicos. Cifrado y almacenamiento seguros.' },
        { title: 'Anal√≠tica Avanzada', description: 'Modelado estad√≠stico y anal√≠tica predictiva. HEOR. An√°lisis coste-efectividad para dossiers Evaluaci√≥n de Tecnolog√≠as Sanitarias (ETS). An√°lisis comparativo transfronterizo.' },
      ],
    },
    therapeuticAreasEs: {
      title: '√Åreas Terap√©uticas',
      areas: [
        { name: 'Oncolog√≠a', description: 'Rutas asistenciales, mapping KOL, adopci√≥n bioterapias' },
        { name: 'Endocrinolog√≠a', description: 'Diabetes, obesidad, tiroides' },
        { name: 'Enfermedades Raras', description: 'Estrategias de acceso, recorrido paciente' },
      ],
    },
    insights: {
      title: '√öltimas Perspectivas',
      subtitle: 'Liderazgo de pensamiento y perspectivas de investigaci√≥n de nuestro equipo global',
      readMore: 'Leer Art√≠culo',
      items: [
        {
          category: 'Acceso al Mercado',
          title: 'El Futuro de los Acuerdos de Salud Basados en Valor en Europa',
          excerpt: 'C√≥mo los modelos de contrataci√≥n innovadores est√°n remodelando las estrategias de precios farmac√©uticos.',
          date: 'Informe Q4 2024',
        },
        {
          category: 'Salud Digital',
          title: 'Descubrimiento de F√°rmacos con IA: Implicaciones de Mercado',
          excerpt: 'An√°lisis del cambio en el panorama competitivo mientras la IA transforma la I+D farmac√©utica.',
          date: 'Brief Estrat√©gico',
        },
        {
          category: 'Oncolog√≠a',
          title: 'Din√°mica del Mercado de Medicina de Precisi√≥n 2025',
          excerpt: 'An√°lisis integral de terapias guiadas por biomarcadores y el paradigma de tratamiento oncol√≥gico.',
          date: 'An√°lisis Industrial',
        },
      ],
    },
    blog: {
      title: '√öltimas Perspectivas',
      subtitle: 'Liderazgo de pensamiento y perspectivas de investigaci√≥n de nuestro equipo global',
      readMore: 'Leer Art√≠culo',
      readMoreArticles: 'Leer m√°s art√≠culos',
      filterAllTopics: 'Todos los temas',
      filterAllCountries: 'Todos los pa√≠ses',
      filterByTopic: 'Tema',
      filterByCountry: 'Pa√≠s',
      items: [
        { category: 'Acceso al Mercado', country: 'Europa', title: 'El Futuro de los Acuerdos de Salud Basados en Valor en Europa', excerpt: 'C√≥mo los modelos de contrataci√≥n innovadores est√°n remodelando las estrategias de precios farmac√©uticos.', date: 'Informe Q4 2024' },
        { category: 'Salud Digital', country: 'EE. UU.', title: 'Descubrimiento de F√°rmacos con IA: Implicaciones de Mercado', excerpt: 'An√°lisis del cambio en el panorama competitivo mientras la IA transforma la I+D farmac√©utica.', date: 'Brief Estrat√©gico' },
        { category: 'Oncolog√≠a', country: 'Reino Unido', title: 'Din√°mica del Mercado de Medicina de Precisi√≥n 2025', excerpt: 'An√°lisis integral de terapias guiadas por biomarcadores y el paradigma de tratamiento oncol√≥gico.', date: 'An√°lisis Industrial' },
      ],
    },
    stats: {
      title: 'Impacto Global',
      items: [
        { value: '50+', label: 'Pa√≠ses Cubiertos' },
        { value: '10+', label: 'Clientes Pharma' },
        { value: '120+', label: 'Proyectos Entregados' },
        { value: '15+', label: 'A√±os de Experiencia' },
      ],
    },
    testimonials: {
      title: 'Perspectivas de Clientes',
      subtitle: 'Confiado por empresas farmac√©uticas y biotecnol√≥gicas l√≠deres en todo el mundo',
      items: [
        { quote: 'BioNixus transform√≥ nuestra estrategia de acceso al mercado con insights rigurosos y accionables. Su perspectiva fue invaluable.', author: 'Dr. Sarah Mitchell', role: 'VP Acceso al Mercado', company: 'Global Pharma Inc.' },
        { quote: 'La profundidad de la inteligencia competitiva y la rapidez de entrega superaron nuestras expectativas. Un verdadero socio estrat√©gico.', author: 'Michael Chen', role: 'Chief Strategy Officer', company: 'BioTech Company' },
        { quote: 'Su mapeo de L√≠deres de Opini√≥n Clave (KOL) y la investigaci√≥n del recorrido del paciente influyeron directamente en nuestro √©xito de lanzamiento en tres mercados europeos clave.', author: 'Dr. Elena Rodriguez', role: 'Director Comercial', company: 'Leading Pharma Company' },
      ],
    },
    contact: {
      title: 'Conectemos',
      subtitle: '¬øListo para transformar su estrategia de mercado sanitario? Nuestro equipo de expertos est√° aqu√≠ para ayudarle.',
      cta: 'Solicitar Propuesta',
      ctaSecondary: 'Explorar Nuestros Servicios',
      email: 'admin@bionixus.com',
      headquarters: 'Wyoming, USA',
      emailLabel: 'Correo',
      headquartersLabel: 'Sede',
      phoneLabel: 'Tel√©fono',
      formTitle: 'Solicitar propuesta',
      firstName: 'Nombre',
      lastName: 'Apellido',
      workEmail: 'Correo profesional',
      company: 'Empresa',
      message: 'Mensaje',
      submitButton: 'Enviar',
      firstNamePlaceholder: 'Juan',
      lastNamePlaceholder: 'Garc√≠a',
      workEmailPlaceholder: 'juan@empresa.com',
      companyPlaceholder: 'Su empresa',
      messagePlaceholder: 'Describa sus necesidades de investigaci√≥n...',
      successTitle: '¬°Gracias!',
      successBody: 'Su consulta ha sido enviada correctamente. Nuestro equipo se pondr√° en contacto con usted en breve.',
      successCaseStudiesText: 'casos de estudio',
      successMethodologyText: 'metodolog√≠a',
      successFollowUpIntro: 'Explore nuestros ',
      successFollowUpBetween: ' o ',
      successFollowUpEnd: ' mientras tanto.',
      validation: {
        firstName: 'Por favor introduzca su nombre',
        lastName: 'Por favor introduzca su apellido',
        workEmail: 'Por favor introduzca un correo profesional v√°lido',
        company: 'Por favor introduzca el nombre de su empresa',
        message: 'Por favor describa c√≥mo podemos ayudarle',
        privacy: 'Por favor acepte la pol√≠tica de privacidad',
        emailFormat: 'Por favor introduzca una direcci√≥n de correo v√°lida',
        success: '¬°Su consulta se ha enviado correctamente!',
        error: 'Ha ocurrido un error. Por favor int√©ntelo de nuevo o cont√°ctenos por correo.',
      },
    },
    localePrompt: {
      title: 'Est√° abriendo desde {region}.',
      question: '¬øDesea cambiar a {language}?',
      yes: 'S√≠',
      no: 'No',
    },
    footer: {
      tagline: 'Investigaci√≥n de Mercado Sanitario | Insights Farmac√©uticos Europa & MENA. Proporcionando insights basados en evidencia a l√≠deres farmac√©uticos y biotech en todo el mundo.',
      companyHeading: 'Empresa',
      about: 'Sobre nosotros',
      services: 'Servicios',
      insights: 'Insights',
      careers: 'Carreras',
      clientsPortal: 'Portal del Cliente',
      caseStudies: 'Casos de Estudio',
      contactHeading: 'Contacto',
      locationUs: 'Wyoming, EE.UU.',
      locationUk: 'Londres, Reino Unido',
      copyright: '¬© 2026 BioNixus. Todos los derechos reservados.',
      privacy: 'Pol√≠tica de privacidad',
      terms: 'T√©rminos de servicio',
    },
    cookieConsent: {
      message: 'Utilizamos cookies para mejorar su experiencia y analizar el tr√°fico del sitio. Al hacer clic en Aceptar, acepta nuestro uso de cookies y nuestra Pol√≠tica de Privacidad.',
      accept: 'Aceptar',
      decline: 'Rechazar',
      privacyLink: 'Pol√≠tica de Privacidad',
    },
  },
  zh: {
    nav: {
      services: 'ÊúçÂä°',
      insights: 'Ê¥ûÂØü',
      about: 'ÂÖ≥‰∫éÊàë‰ª¨',
      contact: 'ËÅîÁ≥ªÊàë‰ª¨',
    },
    hero: {
      tagline: 'Ê¨ßÊ¥≤„ÄÅ‰∏≠‰∏úÂíåÈùûÊ¥≤ÂåªÁñóÂ∏ÇÂú∫Á†îÁ©∂',
      title: 'Ê¨ßÊ¥≤„ÄÅ‰∏≠‰∏úÂíåÈùûÊ¥≤ÂåªÁñóÂ∏ÇÂú∫Á†îÁ©∂ - Âà∂ËçØÂçìË∂ä',
      subtitle: 'Â∞ÜÂåªÁîüÂíåÂåªÈô¢Ê¥ûÂØüËΩ¨Âåñ‰∏∫Ëã±ÂõΩ„ÄÅÊ¨ßÊ¥≤Âèä‰∏≠‰∏úÂíåÈùûÊ¥≤Â∏ÇÂú∫ÁöÑÊàòÁï•Êô∫ËÉΩ',
      valueProposition: 'Êàë‰ª¨Êèê‰æõÂÖ®Èù¢ÁöÑÂÆöÈáèÂíåÂÆöÊÄßÂ∏ÇÂú∫Á†îÁ©∂ÊúçÂä°ÔºåÂ∞Ü‰∏¥Â∫äÊï∞ÊçÆËΩ¨Âåñ‰∏∫ÂèØÊâßË°åÁöÑÂà∂ËçØÊÉÖÊä•„ÄÇÊàë‰ª¨ÁöÑ‰∏ì‰∏öÊñπÊ≥ïÊçïÊçâNHSÂíåÁßÅÁ´ãÂåªÁñóÁ≥ªÁªü‰∏≠ÂåªÁîüÁöÑÁúüÂÆûËßÇÁÇπ„ÄÅÂåªÈô¢Ë∂ãÂäøÂíåÊÇ£ËÄÖÊ¥ûÂØüÔºåË¶ÜÁõñËã±ÂõΩ„ÄÅÊ¨ßÊ¥≤Âíå‰∏≠‰∏úÂíåÈùûÊ¥≤Â∏ÇÂú∫„ÄÇ',
      serviceHighlights: ['Ëã±ÂõΩNHSÂíåÁßÅÁ´ãÂåªÁñóÁ†îÁ©∂', 'Ê≥õÊ¨ßÂåªÁîüË∞ÉÁ†î', 'ÂÆöÊÄßÂÖ≥ÈîÆÊÑèËßÅÈ¢ÜË¢ñ (KOL) ËÆøË∞à', 'Â§öÂõΩÊï∞ÊçÆÂàÜÊûê', 'Ëã±ÂõΩ‚Ä¢Ê¨ßÊ¥≤‚Ä¢‰∏≠‰∏úÂíåÈùûÊ¥≤Ë¶ÜÁõñ'],
      cta: 'Ëé∑ÂèñËã±ÂõΩÁ†îÁ©∂ÊñπÊ°à',
      ctaSecondary: 'Êü•ÁúãÊ¨ßÊ¥≤Ê°à‰æãÁ†îÁ©∂',
      trustBar: 'Âèó‰ª•‰∏ãÂõΩÂÆ∂Âà∂ËçØ‰ºÅ‰∏ö‰ø°Ëµñ',
      trustCountries: 'Ëã±ÂõΩ‚Ä¢Âæ∑ÂõΩ‚Ä¢Ê≥ïÂõΩ‚Ä¢Ë•øÁè≠Áâô‚Ä¢ÊÑèÂ§ßÂà©‚Ä¢ÈòøËÅîÈÖã‚Ä¢Ê≤ôÁâπ‚Ä¢ÂüÉÂèä‚Ä¢ÁßëÂ®ÅÁâπ‚Ä¢Âç°Â°îÂ∞î',
      complianceBadges: ['MHRA Compliant', 'EMA Aligned', 'GDPR Compliant', 'SFDA Compliant', 'ICH-GCP'],
    },
    services: {
      title: 'Ëã±ÂõΩÂèäÊ¨ßÊ¥≤Âà∂ËçØ‰ºÅ‰∏öÁªºÂêàÂåªÁñóÂ∏ÇÂú∫Á†îÁ©∂ÊúçÂä°',
      subtitle: 'Êù•Ëá™Ëã±ÂõΩ„ÄÅÊ¨ßÊ¥≤Âèä‰∏≠‰∏úÂíåÈùûÊ¥≤Âú∞Âå∫ÂåªÁîüÂíåÂåªÈô¢ÁöÑÂÆöÈáè‰∏éÂÆöÊÄßÊ¥ûÂØü',
      items: [
        {
          title: 'ÂÆöÈáèÂåªÁñóÁ†îÁ©∂‰∏éÂåªÁîüË∞ÉÁ†î',
          description: 'Êù•Ëá™Ëã±ÂõΩ„ÄÅÊ¨ßÊ¥≤Âíå‰∏≠‰∏úÂíåÈùûÊ¥≤Âú∞Âå∫ÂåªÁîüÂèäÂåªÁñó‰∏ì‰∏ö‰∫∫ÂëòÁöÑÂ§ßËßÑÊ®°ÁªüËÆ°Ê¥ûÂØü„ÄÇÊúçÂä°ÔºöNHSÂèäÁßÅÁ´ãÊú∫ÊûÑÁ†îÁ©∂„ÄÅÂåªÈô¢ÂÅèÂ•ΩÁ†îÁ©∂„ÄÅÂ§ÑÊñπËøΩË∏™„ÄÅÂç´ÁîüÊäÄÊúØËØÑ‰º∞ÂÜ≥Á≠ñËÄÖÊ¥ûÂØü„ÄÅÊîØ‰ªòÊñπÂàÜÊûê„ÄÅÂ§öÂõΩË∞ÉÁ†îÔºàÈòøËÅîÈÖã„ÄÅÊ≤ôÁâπ„ÄÅÂüÉÂèä„ÄÅÁßëÂ®ÅÁâπ„ÄÅÂç°Â°îÂ∞îÔºâ„ÄÇ‰∫§‰ªòÁâ©ÔºöÁªüËÆ°Êä•Âëä„ÄÅÂ∏ÇÂú∫ËßÑÊ®°„ÄÅË∑ØÂæÑÂàÜÊûê„ÄÅÈ¢ÑÊµã„ÄÅÁªÜÂàÜ„ÄÅÊØîËæÉÊ¥ûÂØü„ÄÇ',
        },
        {
          title: 'ÂÆöÊÄßÂà∂ËçØÁ†îÁ©∂‰∏é‰∏ìÂÆ∂Ê¥ûÂØü',
          description: 'Ê∑±Â∫¶ÂÆöÊÄßÁ†îÁ©∂ÔºåÊçïÊçâËã±ÂõΩ„ÄÅÊ¨ßÊ¥≤Âíå‰∏≠‰∏úÂíåÈùûÊ¥≤Âú∞Âå∫ÁöÑ‰∏¥Â∫äËßÜËßíÂíåÊú™Êª°Ë∂≥ÂåªÁñóÈúÄÊ±Ç„ÄÇÊúçÂä°ÔºöNHSÈ°æÈóÆ/ÂÖ®ÁßëÂåªÁîüËÆøË∞à„ÄÅNICEÂßîÂëò‰ºöÂèÇ‰∏é„ÄÅÊ≥õÊ¨ßKOLÊò†Â∞Ñ„ÄÅÂ§öÂõΩÁÑ¶ÁÇπÂ∞èÁªÑ„ÄÅÊ≤ªÁñóË∑ØÂæÑÂàÜÊûê„ÄÅÊµ∑ÊπæÂåªÁñó‰ΩìÁ≥ªÊ¥ûÂØü„ÄÇ‰∫§‰ªòÁâ©Ôºö‰∏ªÈ¢òÂàÜÊûê„ÄÅÂÖ±ËØÜÊëòË¶Å„ÄÅÂ∏ÇÂú∫ÂáÜÂÖ•Âª∫ËÆÆ„ÄÅKOLÁ≠ñÁï•„ÄÇ',
        },
        {
          title: 'Â∏ÇÂú∫ÂáÜÂÖ•‰∏éÂç´ÁîüÊäÄÊúØËØÑ‰º∞Á≠ñÁï•',
          description: 'NICE„ÄÅG-BA„ÄÅHASÂèäÂç´ÁîüÊäÄÊúØËØÑ‰º∞Êú∫ÊûÑË¶ÅÊ±ÇÊï¥Âêà„ÄÇÂü∫‰∫éËØÅÊçÆÁöÑÂÆö‰ª∑Á≠ñÁï•ÂíåÊîØ‰ªòÊñπÂèÇ‰∏éÊ°ÜÊû∂ÔºåË¶ÜÁõñËã±ÂõΩÂèäÊ¨ßÊ¥≤Â∏ÇÂú∫„ÄÇÊä•ÈîÄÁéØÂ¢ÉÂª∫Ê®°ÂèäÂç´ÁîüÊäÄÊúØËØÑ‰º∞Êèê‰∫§ÁöÑÊàêÊú¨ÊïàÁõäÂàÜÊûê„ÄÇ',
        },
        {
          title: 'KOL‰∏éÂà©ÁõäÁõ∏ÂÖ≥ÊñπÊò†Â∞Ñ',
          description: 'Ëã±ÂõΩÂèäÊ≥õÊ¨ßKOLÊò†Â∞Ñ‰∏éÂèÇ‰∏é„ÄÇNHSÈ°æÈóÆÂèäÁöáÂÆ∂Â≠¶‰ºöÊàêÂëòÁΩëÁªú„ÄÇÂ§öÂõΩÂåªÂ≠¶Âçè‰ºöÂêà‰ΩúÂèäÂåªÈô¢Êèê‰æõÂïÜÂ∞èÁªÑ„ÄÇ',
        },
        {
          title: 'Âú∞ÁêÜË¶ÜÁõñÔºöËã±ÂõΩ‚Ä¢Ê¨ßÊ¥≤‚Ä¢‰∏≠‰∏úÂíåÈùûÊ¥≤',
          description: 'Ëã±ÂõΩÔºöNHSËã±Ê†ºÂÖ∞„ÄÅËãèÊ†ºÂÖ∞„ÄÅÂ®ÅÂ∞îÂ£´„ÄÅÂåóÁà±Â∞îÂÖ∞Ôºõ‰º¶Êï¶ÊïôÂ≠¶ÂåªÈô¢ÔºõNICE„ÄÅMHRAÂà©ÁõäÁõ∏ÂÖ≥ÊñπÁ†îÁ©∂„ÄÇÊ¨ßÊ¥≤ÔºöÂæ∑ÂõΩÔºàG-BA„ÄÅIQWiGÔºâ„ÄÅÊ≥ïÂõΩÔºàHAS„ÄÅCEPSÔºâ„ÄÅË•øÁè≠Áâô„ÄÅÊÑèÂ§ßÂà©„ÄÅËç∑ÂÖ∞„ÄÅÊØîÂà©Êó∂„ÄÅÁëûÂ£´„ÄÇ‰∏≠‰∏úÂíåÈùûÊ¥≤ÔºöÈòøËÅîÈÖãÔºàDHA„ÄÅHAADÔºâ„ÄÅÊ≤ôÁâπÔºà2030ÊÑøÊôØÔºâ„ÄÅÂüÉÂèä„ÄÅÁßëÂ®ÅÁâπ„ÄÅÂç°Â°îÂ∞î„ÄÇ',
        },
        {
          title: 'ÊñπÊ≥ï‰∏éÂêàËßÑ',
          description: 'MHRAÂíåEMAÁõëÁÆ°ÂØπÈΩê„ÄÇGDPRÂêàËßÑÊï∞ÊçÆÊî∂ÈõÜ„ÄÇNHSÁ†îÁ©∂‰º¶ÁêÜÂßîÂëò‰ºöÔºàRECÔºâÊ†áÂáÜ„ÄÇÂ§öËØ≠Ë®ÄË∞ÉÁ†îÈÉ®ÁΩ≤ÔºàËã±„ÄÅÂæ∑„ÄÅÊ≥ï„ÄÅË•ø„ÄÅÊÑè„ÄÅÈòøÊãâ‰ºØËØ≠Ôºâ„ÄÇÂÆâÂÖ®Êï∞ÊçÆÂä†ÂØÜÂèäÂç´ÁîüÁªèÊµéÂ≠¶‰∏éÁªìÊûúÁ†îÁ©∂ (HEOR) ÂàÜÊûê„ÄÇ',
        },
      ],
    },
    geographicCoverageZh: {
      title: 'Âú∞ÁêÜË¶ÜÁõñÔºöÊ¨ßÊ¥≤‚Ä¢‰∏≠‰∏úÂíåÈùûÊ¥≤',
      regions: [
        { name: 'Ê¨ßÊ¥≤ - Ê≥õÊ¨ßÁ†îÁ©∂ÁΩëÁªú', countries: [{ name: 'Âæ∑ÂõΩ', items: ['G-BAÂíåIQWiGÂà©ÁõäÁõ∏ÂÖ≥ÊñπÁ†îÁ©∂', 'ÂåªÈô¢ÂíåÈó®ËØäÊä§ÁêÜ'] }, { name: 'Ê≥ïÂõΩ', items: ['HASÂíåCEPSÂÜ≥Á≠ñËÄÖÊ¥ûÂØü', 'ÂÖ¨Á´ãÂíåÁßÅÁ´ãÂåªÈô¢'] }, { name: 'ÂÖ∂‰ªñÂ∏ÇÂú∫', items: ['Ë•øÁè≠Áâô„ÄÅÊÑèÂ§ßÂà©„ÄÅËç∑ÂÖ∞„ÄÅÊØîÂà©Êó∂„ÄÅÁëûÂ£´', 'ÂüÉÂèä„ÄÅÁßëÂ®ÅÁâπ„ÄÅÂç°Â°îÂ∞î', 'Âú∞Âå∫Âç´ÁîüÁ≥ªÁªüÂíå‰∏ìÁßëÊä§ÁêÜ', 'ÂÖ¨Á´ãÂíåÁßÅÁ´ãÂåªÁñóÁΩëÁªú'] }] },
        { name: '‰∏≠‰∏úÂíåÈùûÊ¥≤ - ÊàòÁï•Â∏ÇÂú∫Êâ©Â±ï', countries: [{ name: 'ÈòøËÅîÈÖã', items: ['DHAÂíåHAADÁõëÁÆ°Êú∫ÊûÑ', 'Ëø™ÊãúÂåªÁñóÂüé'] }, { name: 'Ê≤ôÁâπÈòøÊãâ‰ºØ', items: ['Âç´ÁîüÈÉ®Âíå2030ÊÑøÊôØÂåªÁñóËΩ¨Âûã'] }, { name: 'ÂÖ∂‰ªñÂ∏ÇÂú∫', items: ['ÂüÉÂèä„ÄÅÁßëÂ®ÅÁâπ„ÄÅÂç°Â°îÂ∞î', 'ÂÖ¨Á´ãÂíåÁßÅÁ´ãÂåªÁñóÁΩëÁªú'] }] },
      ],
    },
    methodologyZh: {
      title: 'ÊñπÊ≥ï‰∏éÂêàËßÑ',
      intro: 'Êàë‰ª¨ÁöÑÁ†îÁ©∂ÈÅµÂæ™ÊúÄÈ´òÊ†áÂáÜÁöÑÁõëÁÆ°ÂêàËßÑÂíåÊï∞ÊçÆÂÆâÂÖ®„ÄÇ',
      steps: [
        { title: 'ÁõëÁÆ°ÂØπÈΩê', description: 'MHRAÂíåEMAÁõëÁÆ°ÂêàËßÑ„ÄÇNHSÁ†îÁ©∂‰º¶ÁêÜÂßîÂëò‰ºöÔºàRECÔºâÊ†áÂáÜ„ÄÇGDPRÂêàËßÑÊï∞ÊçÆÊî∂ÈõÜÂçèËÆÆ„ÄÇICH-GCP‰∏¥Â∫äÁ†îÁ©∂ÊåáÂçó„ÄÇ' },
        { title: 'Êï∞ÊçÆÊî∂ÈõÜ‰∏éË¥®Èáè', description: 'Â§öËØ≠Ë®ÄË∞ÉÁ†îÈÉ®ÁΩ≤ÔºàËã±ËØ≠„ÄÅÂæ∑ËØ≠„ÄÅÊ≥ïËØ≠„ÄÅË•øÁè≠ÁâôËØ≠„ÄÅÊÑèÂ§ßÂà©ËØ≠„ÄÅÈòøÊãâ‰ºØËØ≠Ôºâ„ÄÇÂÆûÊó∂Êï∞ÊçÆÈ™åËØÅÂíåË¥®ÈáèÊ£ÄÊü•„ÄÇÂåªÁîüË∫´‰ªΩÈ™åËØÅÂçèËÆÆ„ÄÇÂÆâÂÖ®Êï∞ÊçÆÂä†ÂØÜÂíåÂ≠òÂÇ®„ÄÇ' },
        { title: 'È´òÁ∫ßÂàÜÊûê', description: 'ÁªüËÆ°Âª∫Ê®°ÂíåÈ¢ÑÊµãÂàÜÊûê„ÄÇHEOR„ÄÇÂç´ÁîüÊäÄÊúØËØÑ‰º∞Êèê‰∫§ÁöÑÊàêÊú¨ÊïàÁõäÂàÜÊûê„ÄÇË∑®ÂõΩÊØîËæÉÂàÜÊûê„ÄÇ' },
      ],
    },
    therapeuticAreasZh: {
      title: 'Ê≤ªÁñóÈ¢ÜÂüü',
      areas: [
        { name: 'ËÇøÁò§Â≠¶', description: 'Ê≤ªÁñóË∑ØÂæÑ„ÄÅKOLÊò†Â∞Ñ„ÄÅÁîüÁâ©Âà∂ÂâÇÈááÁî®' },
        { name: 'ÂøÉË°ÄÁÆ°', description: 'ÂøÉÂäõË°∞Á´≠„ÄÅÈ´òË°ÄÂéã„ÄÅÊ≤ªÁñóÊ®°Âºè' },
        { name: 'ÂÜÖÂàÜÊ≥å', description: 'Á≥ñÂ∞øÁóÖ„ÄÅËÇ•ËÉñ„ÄÅÁî≤Áä∂ËÖ∫' },
      ],
    },
    insights: {
      title: 'ÊúÄÊñ∞Ê¥ûÂØü',
      subtitle: 'Êù•Ëá™Êàë‰ª¨ÂÖ®ÁêÉÂõ¢ÈòüÁöÑÊÄùÊÉ≥È¢ÜÂØºÂäõÂíåÁ†îÁ©∂ËßÜËßí',
      readMore: 'ÈòÖËØªÊñáÁ´†',
      items: [
        {
          category: 'Â∏ÇÂú∫ÂáÜÂÖ•',
          title: 'Ê¨ßÊ¥≤Âü∫‰∫é‰ª∑ÂÄºÁöÑÂåªÁñóÂçèËÆÆÁöÑÊú™Êù•',
          excerpt: 'ÂàõÊñ∞ÂêàÂêåÊ®°ÂºèÂ¶Ç‰ΩïÈáçÂ°ë‰∏ªË¶ÅÊ¨ßÊ¥≤Â∏ÇÂú∫ÁöÑÂà∂ËçØÂÆö‰ª∑ÂíåÂáÜÂÖ•Á≠ñÁï•„ÄÇ',
          date: '2024Âπ¥Á¨¨ÂõõÂ≠£Â∫¶Êä•Âëä',
        },
        {
          category: 'Êï∞Â≠óÂÅ•Â∫∑',
          title: 'AIÈ©±Âä®ÁöÑËçØÁâ©ÂèëÁé∞ÔºöÂ∏ÇÂú∫ÂΩ±Âìç',
          excerpt: 'ÂàÜÊûê‰∫∫Â∑•Êô∫ËÉΩÊîπÂèòÂà∂ËçØÁ†îÂèëÂíå‰∏äÂ∏ÇÊó∂Èó¥Êó∂ÁöÑÁ´û‰∫âÊ†ºÂ±ÄÂèòÂåñ„ÄÇ',
          date: 'ÊàòÁï•ÁÆÄÊä•',
        },
        {
          category: 'ËÇøÁò§Â≠¶',
          title: '2025Âπ¥Á≤æÂáÜÂåªÁñóÂ∏ÇÂú∫Âä®ÊÄÅ',
          excerpt: 'ÂØπÁîüÁâ©Ê†áÂøóÁâ©È©±Âä®ÁñóÊ≥ïÂíå‰∏çÊñ≠ÂèëÂ±ïÁöÑËÇøÁò§Ê≤ªÁñóËåÉÂºèÁöÑÂÖ®Èù¢ÂàÜÊûê„ÄÇ',
          date: 'Ë°å‰∏öÂàÜÊûê',
        },
      ],
    },
    blog: {
      title: 'ÊúÄÊñ∞Ê¥ûÂØü',
      subtitle: 'Êù•Ëá™Êàë‰ª¨ÂÖ®ÁêÉÂõ¢ÈòüÁöÑÊÄùÊÉ≥È¢ÜÂØºÂäõÂíåÁ†îÁ©∂ËßÜËßí',
      readMore: 'ÈòÖËØªÊñáÁ´†',
      readMoreArticles: 'ÈòÖËØªÊõ¥Â§öÊñáÁ´†',
      filterAllTopics: 'ÂÖ®ÈÉ®‰∏ªÈ¢ò',
      filterAllCountries: 'ÂÖ®ÈÉ®ÂõΩÂÆ∂',
      filterByTopic: '‰∏ªÈ¢ò',
      filterByCountry: 'ÂõΩÂÆ∂',
      items: [
        { category: 'Â∏ÇÂú∫ÂáÜÂÖ•', country: 'Ê¨ßÊ¥≤', title: 'Ê¨ßÊ¥≤Âü∫‰∫é‰ª∑ÂÄºÁöÑÂåªÁñóÂçèËÆÆÁöÑÊú™Êù•', excerpt: 'ÂàõÊñ∞ÂêàÂêåÊ®°ÂºèÂ¶Ç‰ΩïÈáçÂ°ë‰∏ªË¶ÅÊ¨ßÊ¥≤Â∏ÇÂú∫ÁöÑÂà∂ËçØÂÆö‰ª∑ÂíåÂáÜÂÖ•Á≠ñÁï•„ÄÇ', date: '2024Âπ¥Á¨¨ÂõõÂ≠£Â∫¶Êä•Âëä' },
        { category: 'Êï∞Â≠óÂÅ•Â∫∑', country: 'ÁæéÂõΩ', title: 'AIÈ©±Âä®ÁöÑËçØÁâ©ÂèëÁé∞ÔºöÂ∏ÇÂú∫ÂΩ±Âìç', excerpt: 'ÂàÜÊûê‰∫∫Â∑•Êô∫ËÉΩÊîπÂèòÂà∂ËçØÁ†îÂèëÂíå‰∏äÂ∏ÇÊó∂Èó¥Êó∂ÁöÑÁ´û‰∫âÊ†ºÂ±ÄÂèòÂåñ„ÄÇ', date: 'ÊàòÁï•ÁÆÄÊä•' },
        { category: 'ËÇøÁò§Â≠¶', country: 'Ëã±ÂõΩ', title: '2025Âπ¥Á≤æÂáÜÂåªÁñóÂ∏ÇÂú∫Âä®ÊÄÅ', excerpt: 'ÂØπÁîüÁâ©Ê†áÂøóÁâ©È©±Âä®ÁñóÊ≥ïÂíå‰∏çÊñ≠ÂèëÂ±ïÁöÑËÇøÁò§Ê≤ªÁñóËåÉÂºèÁöÑÂÖ®Èù¢ÂàÜÊûê„ÄÇ', date: 'Ë°å‰∏öÂàÜÊûê' },
      ],
    },
    stats: {
      title: 'ÂÖ®ÁêÉÂΩ±Âìç',
      items: [
        { value: '50+', label: 'Ë¶ÜÁõñÂõΩÂÆ∂' },
        { value: '10+', label: 'Âà∂ËçØÂÆ¢Êà∑' },
        { value: '120+', label: '‰∫§‰ªòÈ°πÁõÆ' },
        { value: '15+', label: 'Âπ¥ÁªèÈ™å' },
      ],
    },
    testimonials: {
      title: 'ÂÆ¢Êà∑ËßÇÁÇπ',
      subtitle: 'ÂèóÂà∞ÂÖ®ÁêÉÈ¢ÜÂÖàÂà∂ËçØÂíåÁîüÁâ©ÊäÄÊúØÂÖ¨Âè∏ÁöÑ‰ø°Ëµñ',
      items: [
        { quote: 'BioNixus‰ª•‰∏•Ë∞®‰∏îÂèØÊâßË°åÁöÑÊ¥ûÂØüËΩ¨Âèò‰∫ÜÊàë‰ª¨ÁöÑÂ∏ÇÂú∫ÂáÜÂÖ•Á≠ñÁï•„ÄÇ‰ªñ‰ª¨ÁöÑËßÜËßíÊûÅÂÖ∑‰ª∑ÂÄº„ÄÇ', author: 'Dr. Sarah Mitchell', role: 'Â∏ÇÂú∫ÂáÜÂÖ•ÂâØÊÄªË£Å', company: 'Global Pharma Inc.' },
        { quote: 'Á´û‰∫âÊÉÖÊä•ÁöÑÊ∑±Â∫¶Âíå‰∫§‰ªòÈÄüÂ∫¶ÂùáÊòæËëóË∂ÖÂá∫‰∫ÜÊàë‰ª¨ÁöÑÈ¢ÑÊúü„ÄÇ‰ªñ‰ª¨Â†™Áß∞ÁúüÊ≠£ÁöÑÊàòÁï•Âêà‰Ωú‰ºô‰º¥„ÄÇ', author: 'Michael Chen', role: 'È¶ñÂ∏≠ÊàòÁï•ÂÆò', company: 'BioTech Company' },
        { quote: '‰ªñ‰ª¨ÁöÑÂÖ≥ÈîÆÊÑèËßÅÈ¢ÜË¢ñ (KOL) Êò†Â∞ÑÂíåÊÇ£ËÄÖÊóÖÁ®ãÁ†îÁ©∂Áõ¥Êé•ÂΩ±Âìç‰∫ÜÊàë‰ª¨Âú®‰∏âÂ§ßÊ¨ßÊ¥≤Â∏ÇÂú∫ÁöÑ‰∏äÂ∏ÇÊàêÂäü„ÄÇ', author: 'Dr. Elena Rodriguez', role: 'ÂïÜ‰∏öÊÄªÁõë', company: 'Leading Pharma Company' },
      ],
    },
    contact: {
      title: 'ËÅîÁ≥ªÊàë‰ª¨',
      subtitle: 'ÂáÜÂ§áÂ•ΩËΩ¨ÂèòÊÇ®ÁöÑÂåªÁñóÂ∏ÇÂú∫ÊàòÁï•‰∫ÜÂêóÔºüÊàë‰ª¨ÁöÑ‰∏ìÂÆ∂Âõ¢ÈòüÈöèÊó∂‰∏∫ÊÇ®ÊúçÂä°„ÄÇ',
      cta: 'Á¥¢ÂèñÊñπÊ°à',
      ctaSecondary: 'Êé¢Á¥¢Êàë‰ª¨ÁöÑÊúçÂä°',
      email: 'admin@bionixus.com',
      headquarters: 'Wyoming, USA',
      emailLabel: 'ÈÇÆÁÆ±',
      headquartersLabel: 'ÊÄªÈÉ®',
      phoneLabel: 'ÁîµËØù',
      formTitle: 'Á¥¢ÂèñÊñπÊ°à',
      firstName: 'Âêç',
      lastName: 'Âßì',
      workEmail: 'Â∑•‰ΩúÈÇÆÁÆ±',
      company: 'ÂÖ¨Âè∏',
      message: 'ÁïôË®Ä',
      submitButton: 'Êèê‰∫§',
      firstNamePlaceholder: 'Âº†',
      lastNamePlaceholder: '‰ºü',
      workEmailPlaceholder: 'zhang@company.com',
      companyPlaceholder: 'ÊÇ®ÁöÑÂÖ¨Âè∏',
      messagePlaceholder: 'ËØ∑ÊèèËø∞ÊÇ®ÁöÑÁ†îÁ©∂ÈúÄÊ±Ç...',
      successTitle: 'ÊÑüË∞¢ÊÇ®ÔºÅ',
      successBody: 'ÊÇ®ÁöÑÂí®ËØ¢Â∑≤ÊàêÂäüÊèê‰∫§„ÄÇÊàë‰ª¨ÁöÑÂõ¢ÈòüÂ∞ÜÂ∞ΩÂø´‰∏éÊÇ®ËÅîÁ≥ª„ÄÇ',
      successCaseStudiesText: 'Ê°à‰æãÁ†îÁ©∂',
      successMethodologyText: 'ÊñπÊ≥ïËÆ∫',
      successFollowUpIntro: 'Âú®Á≠âÂæÖÊúüÈó¥ÔºåÊÇ®ÂèØ‰ª•ÊµèËßàÊàë‰ª¨ÁöÑ',
      successFollowUpBetween: 'Êàñ',
      successFollowUpEnd: 'ÈÉ®ÂàÜ„ÄÇ',
      validation: {
        firstName: 'ËØ∑ËæìÂÖ•ÊÇ®ÁöÑÂêçÂ≠ó',
        lastName: 'ËØ∑ËæìÂÖ•ÊÇ®ÁöÑÂßìÊ∞è',
        workEmail: 'ËØ∑ËæìÂÖ•ÊúâÊïàÁöÑÂ∑•‰ΩúÈÇÆÁÆ±',
        company: 'ËØ∑ËæìÂÖ•ÂÖ¨Âè∏ÂêçÁß∞',
        message: 'ËØ∑ÊèèËø∞Êàë‰ª¨Â¶Ç‰ΩïÂ∏ÆÂä©ÊÇ®',
        privacy: 'ËØ∑Êé•ÂèóÈöêÁßÅÊîøÁ≠ñ',
        emailFormat: 'ËØ∑ËæìÂÖ•ÊúâÊïàÁöÑÈÇÆÁÆ±Âú∞ÂùÄ',
        success: 'ÊÇ®ÁöÑÂí®ËØ¢Â∑≤ÊàêÂäüÊèê‰∫§ÔºÅ',
        error: 'ÂèëÁîüÈîôËØØ„ÄÇËØ∑ÈáçËØïÊàñÁõ¥Êé•ÈÄöËøáÁîµÂ≠êÈÇÆ‰ª∂ËÅîÁ≥ªÊàë‰ª¨„ÄÇ',
      },
    },
    localePrompt: {
      title: 'ÊÇ®Ê≠£Âú®‰ªé {region} ÊâìÂºÄ„ÄÇ',
      question: 'ÊòØÂê¶ÂàáÊç¢Âà∞ {language}Ôºü',
      yes: 'ÊòØ',
      no: 'Âê¶',
    },
    footer: {
      tagline: 'ÂåªÁñóÂ∏ÇÂú∫Á†îÁ©∂ | Ê¨ßÊ¥≤Âèä‰∏≠‰∏úÂíåÈùûÊ¥≤Âà∂ËçØÊ¥ûÂØü„ÄÇ‰∏∫ÂÖ®ÁêÉÂà∂ËçØÂíåÁîüÁâ©ÊäÄÊúØÈ¢ÜÂØºËÄÖÊèê‰æõÂü∫‰∫éËØÅÊçÆÁöÑÊ¥ûÂØü„ÄÇ',
      companyHeading: 'ÂÖ¨Âè∏',
      about: 'ÂÖ≥‰∫éÊàë‰ª¨',
      services: 'ÊúçÂä°',
      insights: 'Ê¥ûÂØü',
      careers: 'ËÅå‰∏ö',
      clientsPortal: 'ÂÆ¢Êà∑Èó®Êà∑',
      caseStudies: 'Ê°à‰æãÁ†îÁ©∂',
      contactHeading: 'ËÅîÁ≥ªÊñπÂºè',
      locationUs: 'ÁæéÂõΩÊÄÄ‰øÑÊòéÂ∑û',
      locationUk: 'Ëã±ÂõΩ‰º¶Êï¶',
      copyright: '¬© 2026 BioNixus. ‰øùÁïôÊâÄÊúâÊùÉÂà©„ÄÇ',
      privacy: 'ÈöêÁßÅÊîøÁ≠ñ',
      terms: 'ÊúçÂä°Êù°Ê¨æ',
    },
    cookieConsent: {
      message: 'Êàë‰ª¨‰ΩøÁî® Cookie Êù•ÊîπÂñÑÊÇ®ÁöÑ‰ΩìÈ™åÂπ∂ÂàÜÊûêÁΩëÁ´ôÊµÅÈáè„ÄÇÁÇπÂáª‚ÄúÊé•Âèó‚ÄùÂç≥Ë°®Á§∫ÊÇ®ÂêåÊÑèÊàë‰ª¨‰ΩøÁî® Cookie ÂíåÊàë‰ª¨ÁöÑÈöêÁßÅÊîøÁ≠ñ„ÄÇ',
      accept: 'Êé•Âèó',
      decline: 'ÊãíÁªù',
      privacyLink: 'ÈöêÁßÅÊîøÁ≠ñ',
    },
  },
  ar: {
    nav: {
      services: 'ÿßŸÑÿÆÿØŸÖÿßÿ™',
      insights: 'ÿßŸÑÿ±ÿ§Ÿâ',
      about: 'ŸÖŸÜ ŸÜÿ≠ŸÜ',
      contact: 'ÿßÿ™ÿµŸÑ ÿ®ŸÜÿß',
    },
    hero: {
      tagline: 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑÿµÿ≠Ÿäÿ© ŸÅŸä ÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑ ŸàÿßŸÑÿÆŸÑŸäÿ¨',
      title: 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑÿµÿ≠Ÿäÿ© ŸàÿßŸÑÿØŸàÿßÿ¶Ÿäÿ© ŸÅŸä ÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑ ŸàÿØŸàŸÑ ÿßŸÑÿÆŸÑŸäÿ¨',
      subtitle: 'ÿ≠ŸàŸëŸÑ ÿ±ÿ§Ÿâ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸàÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿ•ŸÑŸâ ÿ∞ŸÉÿßÿ° ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä ÿπÿ®ÿ± ÿ£ÿ≥ŸàÿßŸÇ ÿßŸÑÿÆŸÑŸäÿ¨ Ÿàÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß',
      valueProposition: 'ŸÜŸÇÿØŸÖ ÿÆÿØŸÖÿßÿ™ ÿ£ÿ®ÿ≠ÿßÿ´ ÿ≥ŸàŸÇ ŸÉŸÖŸäÿ© ŸàŸÜŸàÿπŸäÿ© ÿ¥ÿßŸÖŸÑÿ© ÿ™ÿ≠ŸàŸÑ ÿßŸÑÿ®ŸäÿßŸÜÿßÿ™ ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿäÿ© ÿ•ŸÑŸâ ŸÖÿπŸÑŸàŸÖÿßÿ™ ÿØŸàÿßÿ¶Ÿäÿ© ŸÇÿßÿ®ŸÑÿ© ŸÑŸÑÿ™ŸÜŸÅŸäÿ∞. ŸÖŸÜŸáÿ¨Ÿäÿ™ŸÜÿß ÿßŸÑŸÖÿ™ÿÆÿµÿµÿ© ÿ™ŸÑÿ™ŸÇÿ∑ Ÿàÿ¨Ÿáÿßÿ™ ŸÜÿ∏ÿ± ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑÿ≠ŸÇŸäŸÇŸäÿ© ŸÖŸÜ ÿßŸÑŸÇÿ∑ÿßÿπŸäŸÜ ÿßŸÑÿ≠ŸÉŸàŸÖŸä ŸàÿßŸÑÿÆÿßÿµÿå ÿßÿ™ÿ¨ÿßŸáÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ÿå Ÿàÿ±ÿ§Ÿâ ÿßŸÑŸÖÿ±ÿ∂Ÿâ ÿπÿ®ÿ± ÿ£ÿ≥ŸàÿßŸÇ ÿØŸàŸÑ ÿßŸÑÿÆŸÑŸäÿ¨ ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑ ŸÑÿØÿπŸÖ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿßÿ™ ÿ™ÿ∑ŸàŸäÿ± ÿßŸÑÿ£ÿØŸàŸäÿ©ÿå ÿßŸÑŸàÿµŸàŸÑ ŸÑŸÑÿ≥ŸàŸÇÿå ŸàÿßŸÑÿ™ÿ≥ŸàŸäŸÇ ÿßŸÑÿ™ÿ¨ÿßÿ±Ÿä.',
      serviceHighlights: ['ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ≠ŸÉŸàŸÖŸäÿ© ŸàÿßŸÑÿÆÿßÿµÿ©', 'ÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑŸÉŸÖŸäÿ©', 'ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ÿßŸÑÿÆÿ®ÿ±ÿßÿ° ÿßŸÑŸÜŸàÿπŸäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ®ŸäÿßŸÜÿßÿ™ ŸÖÿ™ÿπÿØÿØ ÿßŸÑÿØŸàŸÑ', 'ÿ™ÿ∫ÿ∑Ÿäÿ© ÿ¥ÿßŸÖŸÑÿ© ŸÑŸÑÿÆŸÑŸäÿ¨ ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑'],
      cta: 'ÿßÿ≠ÿµŸÑ ÿπŸÑŸâ ÿπÿ±ÿ∂ ÿ£ÿ≥ÿπÿßÿ±',
      ctaSecondary: 'ÿßÿ≥ÿ™ÿπÿ±ÿ∂ ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑÿ≠ÿßŸÑÿ©',
      trustBar: 'ŸÖŸàÿ´ŸàŸÇ ÿ®Ÿá ŸÖŸÜ ŸÇÿ®ŸÑ ÿ¥ÿ±ŸÉÿßÿ™ ÿßŸÑÿ£ÿØŸàŸäÿ© ŸÅŸä',
      trustCountries: 'ÿßŸÑÿ≥ÿπŸàÿØŸäÿ© ‚Ä¢ ÿßŸÑÿ•ŸÖÿßÿ±ÿßÿ™ ‚Ä¢ ÿßŸÑŸÉŸàŸäÿ™ ‚Ä¢ ŸÇÿ∑ÿ± ‚Ä¢ ŸÖÿµÿ± ‚Ä¢ ÿßŸÑŸÖÿ∫ÿ±ÿ® ‚Ä¢ ÿßŸÑÿ¨ÿ≤ÿßÿ¶ÿ± ‚Ä¢ ÿ™ŸàŸÜÿ≥',
      complianceBadges: ['MHRA Compliant', 'EMA Aligned', 'GDPR Compliant', 'SFDA Compliant', 'ICH-GCP'],
    },
    services: {
      title: 'ÿÆÿ®ÿ±ÿ™ŸÜÿß',
      subtitle: 'ÿ≠ŸÑŸàŸÑ ÿ¥ÿßŸÖŸÑÿ© ŸÑÿ£ÿ®ÿ≠ÿßÿ´ ÿ≥ŸàŸÇ ÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿµÿ≠Ÿäÿ© ŸÖÿµŸÖŸÖÿ© ŸàŸÅŸÇÿßŸã ŸÑÿßÿ≠ÿ™Ÿäÿßÿ¨ÿßÿ™ŸÉ ÿßŸÑÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ©',
      servicePrimaryAr: [
        {
          title: 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑŸÉŸÖŸäÿ© Ÿàÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸÅŸä ÿØŸàŸÑ ÿßŸÑÿÆŸÑŸäÿ¨ ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑',
          lead: 'ÿ±ÿ§Ÿâ ÿ•ÿ≠ÿµÿßÿ¶Ÿäÿ© ŸÇŸàŸäÿ© ŸÖŸÜ ÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ Ÿàÿßÿ≥ÿπÿ© ÿßŸÑŸÜÿ∑ÿßŸÇ ŸÑŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸàÿßŸÑŸÖŸáŸÜŸäŸäŸÜ ÿßŸÑÿµÿ≠ŸäŸäŸÜ ÿπÿ®ÿ± ÿ£ÿ≥ŸàÿßŸÇ ÿßŸÑÿÆŸÑŸäÿ¨ÿå ÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑. ŸÖŸÜŸáÿ¨Ÿäÿßÿ™ŸÜÿß ÿßŸÑŸÉŸÖŸäÿ© ÿ™ŸÇÿØŸÖ ÿßŸÑÿ£ÿØŸÑÿ© ÿßŸÑÿ™Ÿä ÿ™ÿ≠ÿ™ÿßÿ¨Ÿáÿß ŸÑÿßÿ™ÿÆÿßÿ∞ ŸÇÿ±ÿßÿ±ÿßÿ™ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ©.',
          countries: [
            { name: 'ÿßŸÑŸÖŸÖŸÑŸÉÿ© ÿßŸÑÿπÿ±ÿ®Ÿäÿ© ÿßŸÑÿ≥ÿπŸàÿØŸäÿ©', items: ['ÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ ÿ£ÿ∑ÿ®ÿßÿ° Ÿàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ© ŸàÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© ŸàÿßŸÑÿ™ÿÆÿµÿµŸäÿ© (ÿßŸÑÿ±Ÿäÿßÿ∂ÿå ÿ¨ÿØÿ©ÿå ÿßŸÑÿØŸÖÿßŸÖ)', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ≥ŸÑŸàŸÉ ÿßŸÑŸàÿµŸÅÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ© ŸàÿßŸÑÿ™ŸÅÿ∂ŸäŸÑÿßÿ™ ÿßŸÑÿπŸÑÿßÿ¨Ÿäÿ©', 'ÿ£ÿ®ÿ≠ÿßÿ´ ŸÖÿØŸÜ ÿßŸÑŸÖŸÑŸÉ ŸÅŸáÿØ ÿßŸÑÿ∑ÿ®Ÿäÿ© ŸàŸÖÿ¨ŸÖÿπ ÿßŸÑŸÖŸÑŸÉ ÿπÿ®ÿØÿßŸÑŸÑŸá ÿßŸÑÿ∑ÿ®Ÿä', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿ±ÿ§Ÿäÿ© 2030 ŸàÿßŸÑÿ™ÿ≠ŸàŸÑ ÿßŸÑÿµÿ≠Ÿä', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ≠ÿ¨ŸÖ ÿßŸÑÿ≥ŸàŸÇ ŸàÿßŸÑÿ™ŸÜÿ®ÿ§ ÿ®ÿßŸÑÿßÿ™ÿ¨ÿßŸáÿßÿ™'] },
            { name: 'ÿßŸÑÿ•ŸÖÿßÿ±ÿßÿ™ ÿßŸÑÿπÿ±ÿ®Ÿäÿ© ÿßŸÑŸÖÿ™ÿ≠ÿØÿ©', items: ['ÿ£ÿ®ÿ≠ÿßÿ´ ŸáŸäÿ¶ÿ© ÿßŸÑÿµÿ≠ÿ© ÿ®ÿØÿ®Ÿä (DHA) ŸàÿØÿßÿ¶ÿ±ÿ© ÿßŸÑÿµÿ≠ÿ© ÿ£ÿ®Ÿàÿ∏ÿ®Ÿä (DOH)', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿÆÿßÿµÿ© ŸàÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ≥Ÿäÿßÿ≠ÿ© ÿßŸÑÿπŸÑÿßÿ¨Ÿäÿ© ŸàÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸÅŸä ÿØÿ®Ÿäÿå ÿ£ÿ®Ÿàÿ∏ÿ®Ÿäÿå ÿßŸÑÿ¥ÿßÿ±ŸÇÿ©', 'ÿ£ÿ®ÿ≠ÿßÿ´ ŸÖÿØŸäŸÜÿ© ÿØÿ®Ÿä ÿßŸÑÿ∑ÿ®Ÿäÿ© ŸàŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ŸÉŸÑŸäŸÅŸÑÿßŸÜÿØ ŸÉŸÑŸäŸÜŸÉ'] },
            { name: 'ÿßŸÑŸÉŸàŸäÿ™', items: ['ÿØÿ±ÿßÿ≥ÿßÿ™ ŸÜÿ∏ÿßŸÖ ÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿµÿ≠Ÿäÿ© ÿ®Ÿàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ©', 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ© ŸàÿßŸÑŸÖÿ¨ŸÖÿπÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ™ŸÅÿ∂ŸäŸÑÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸàÿßŸÑÿ£ŸÜŸÖÿßÿ∑ ÿßŸÑÿπŸÑÿßÿ¨Ÿäÿ©'] },
            { name: 'ŸÇÿ∑ÿ±', items: ['ÿ£ÿ®ÿ≠ÿßÿ´ ŸÖÿ§ÿ≥ÿ≥ÿ© ÿ≠ŸÖÿØ ÿßŸÑÿ∑ÿ®Ÿäÿ© ŸàÿßŸÑŸÖÿ§ÿ≥ÿ≥ÿßÿ™ ÿßŸÑÿµÿ≠Ÿäÿ©', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿÆÿßÿµÿ© ŸàÿßŸÑÿπŸäÿßÿØÿßÿ™ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖÿ®ÿßÿØÿ±ÿßÿ™ ÿßŸÑÿµÿ≠Ÿäÿ© ŸàÿßŸÑÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ÿßŸÑŸàÿ∑ŸÜŸäÿ© ŸÑŸÑÿµÿ≠ÿ©'] },
            { name: 'ŸÖÿµÿ±', items: ['ÿ£ÿ®ÿ≠ÿßÿ´ ÿ£ŸÉÿ®ÿ± ÿ≥ŸàŸÇ ÿØŸàÿßÿ¶Ÿä ŸÅŸä ÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß', 'ÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ≠ŸÉŸàŸÖŸäÿ© ŸàÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© (ÿßŸÑŸÇÿßŸáÿ±ÿ©ÿå ÿßŸÑÿ•ÿ≥ŸÉŸÜÿØÿ±Ÿäÿ©)', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ ŸàÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ∑ÿ®Ÿäÿ© ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ¥ÿ®ŸÉÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ŸàÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿ£ŸàŸÑŸäÿ©', 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ™ÿ£ŸÖŸäŸÜ ÿßŸÑÿµÿ≠Ÿä ÿßŸÑÿ¥ÿßŸÖŸÑ'] },
            { name: 'ÿßŸÑŸÖÿ∫ÿ±ÿ®', items: ['ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿä ŸÅŸä ÿßŸÑÿ±ÿ®ÿßÿ∑ÿå ÿßŸÑÿØÿßÿ± ÿßŸÑÿ®Ÿäÿ∂ÿßÿ°ÿå ŸÖÿ±ÿßŸÉÿ¥', 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© CHU', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ ŸàÿßŸÑÿπŸäÿßÿØÿßÿ™ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©'] },
            { name: 'ÿßŸÑÿ¨ÿ≤ÿßÿ¶ÿ±', items: ['ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿµÿ≠Ÿä ÿßŸÑÿπÿßŸÖ ŸàÿßŸÑÿÆÿßÿµ', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© ŸÅŸä ÿßŸÑÿ¨ÿ≤ÿßÿ¶ÿ±ÿå ŸàŸáÿ±ÿßŸÜÿå ŸÇÿ≥ŸÜÿ∑ŸäŸÜÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ≥ŸàŸÇ ÿßŸÑÿ£ÿØŸàŸäÿ© ŸàÿßŸÑÿ™Ÿàÿ≤Ÿäÿπ'] },
            { name: 'ÿ™ŸàŸÜÿ≥', items: ['ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿä ÿßŸÑŸàÿ∑ŸÜŸä', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© ŸàÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑŸÖÿ™ÿÆÿµÿµÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ ÿßŸÑÿµÿ≠Ÿä'] },
            { name: 'ÿ•Ÿäÿ±ÿßŸÜ', items: ['ÿ£ÿ®ÿ≠ÿßÿ´ ÿ≥ŸàŸÇ ÿßŸÑÿ£ÿØŸàŸäÿ© ÿßŸÑÿ•Ÿäÿ±ÿßŸÜŸä', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ŸàÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ© ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿä ŸàÿßŸÑÿ™ÿµŸÜŸäÿπ ÿßŸÑŸÖÿ≠ŸÑŸä ŸÑŸÑÿ£ÿØŸàŸäÿ©'] },
          ],
          deliverables: 'ÿßŸÑŸÖÿÆÿ±ÿ¨ÿßÿ™: ÿ™ŸÇÿßÿ±Ÿäÿ± ÿ•ÿ≠ÿµÿßÿ¶Ÿäÿ© ÿ¥ÿßŸÖŸÑÿ©ÿå ÿ™ŸÇÿØŸäÿ±ÿßÿ™ ÿ≠ÿ¨ŸÖ ÿßŸÑÿ≥ŸàŸÇÿå ÿ™ÿ≠ŸÑŸäŸÑ ŸÖÿ≥ÿßÿ±ÿßÿ™ ÿßŸÑÿπŸÑÿßÿ¨ÿå ÿßŸÑÿ™ŸÜÿ®ÿ§ ÿ®ÿßŸÑÿßÿ™ÿ¨ÿßŸáÿßÿ™ÿå ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ™ŸÇÿ≥ŸäŸÖÿå ÿ±ÿ§Ÿâ ŸÖŸÇÿßÿ±ŸÜÿ© ÿπÿ®ÿ± ÿßŸÑÿØŸàŸÑÿå ŸÑŸàÿ≠ÿßÿ™ ÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿä',
        },
        {
          title: 'ÿßŸÑÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÜŸàÿπŸäÿ© Ÿàÿ±ÿ§Ÿâ ÿßŸÑÿÆÿ®ÿ±ÿßÿ° ÿßŸÑÿ∑ÿ®ŸäŸäŸÜ ŸÅŸä ÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑',
          lead: 'ÿ£ÿ®ÿ≠ÿßÿ´ ŸÜŸàÿπŸäÿ© ŸÖÿ™ÿπŸÖŸÇÿ© ÿ™ŸÑÿ™ŸÇÿ∑ Ÿàÿ¨Ÿáÿßÿ™ ÿßŸÑŸÜÿ∏ÿ± ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿäÿ© ÿßŸÑÿØŸÇŸäŸÇÿ©ÿå ÿßŸÑÿßÿ≠ÿ™Ÿäÿßÿ¨ÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ© ÿ∫Ÿäÿ± ÿßŸÑŸÖŸÑÿ®ÿßÿ©ÿå ŸàÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä ŸÖŸÜ ÿÆŸÑÿßŸÑ ÿßŸÑÿ™ŸÅÿßÿπŸÑ ŸÖÿπ ÿßŸÑÿÆÿ®ÿ±ÿßÿ° ÿπÿ®ÿ± ÿßŸÑÿ£ÿ≥ŸàÿßŸÇ ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿäÿ©.',
          countries: [
            { name: 'ÿßŸÑŸÖŸÖŸÑŸÉÿ© ÿßŸÑÿπÿ±ÿ®Ÿäÿ© ÿßŸÑÿ≥ÿπŸàÿØŸäÿ© - ÿßŸÑÿ®ÿ≠ÿ´ ÿßŸÑŸÜŸàÿπŸä', items: ['ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ŸÖÿ™ÿπŸÖŸÇÿ© ŸÖÿπ ÿßÿ≥ÿ™ÿ¥ÿßÿ±ŸäŸäŸÜ Ÿàÿ£ÿ∑ÿ®ÿßÿ° ŸÖÿ™ÿÆÿµÿµŸäŸÜ', 'ŸÖÿ¨ŸÖŸàÿπÿßÿ™ ÿßŸÑŸÜŸÇÿßÿ¥ ŸÖÿπ ŸÖÿØŸäÿ±Ÿä ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™', 'ŸÖÿ¨ÿßŸÑÿ≥ ÿßÿ≥ÿ™ÿ¥ÿßÿ±Ÿäÿ© ŸÑŸÑÿÆÿ®ÿ±ÿßÿ° ÿßŸÑÿ∑ÿ®ŸäŸäŸÜ KOL', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿ™ÿ¨ÿ±ÿ®ÿ© ÿßŸÑŸÖÿ±ÿ∂Ÿâ', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿßÿ≠ÿ™Ÿäÿßÿ¨ÿßÿ™ ÿ∫Ÿäÿ± ÿßŸÑŸÖŸÑÿ®ÿßÿ© ŸÅŸä ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿπŸÑÿßÿ¨Ÿäÿ©'] },
            { name: 'ÿßŸÑÿ•ŸÖÿßÿ±ÿßÿ™ ÿßŸÑÿπÿ±ÿ®Ÿäÿ© ÿßŸÑŸÖÿ™ÿ≠ÿØÿ© - ÿ±ÿ§Ÿâ ÿßŸÑÿÆÿ®ÿ±ÿßÿ°', items: ['ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑÿßÿ≥ÿ™ÿ¥ÿßÿ±ŸäŸäŸÜ ŸÅŸä ÿßŸÑŸÇÿ∑ÿßÿπŸäŸÜ ÿßŸÑÿπÿßŸÖ ŸàÿßŸÑÿÆÿßÿµ', 'ÿ¨ŸÑÿ≥ÿßÿ™ ÿßŸÑÿÆÿ®ÿ±ÿßÿ° ÿßŸÑÿ∑ÿ®ŸäŸäŸÜ ŸàÿßŸÑŸÇÿßÿØÿ© ÿßŸÑÿ±ÿ£Ÿä KOL', 'ŸÖÿ¨ŸÖŸàÿπÿßÿ™ ÿßŸÑÿ™ÿ±ŸÉŸäÿ≤ ŸÖÿπ ÿßŸÑŸÖŸáŸÜŸäŸäŸÜ ÿßŸÑÿµÿ≠ŸäŸäŸÜ', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ŸÖÿ≥ÿßÿ±ÿßÿ™ ÿßŸÑÿπŸÑÿßÿ¨ ÿπÿ®ÿ± ÿßŸÑÿ≠ÿØŸàÿØ'] },
            { name: 'ÿßŸÑŸÉŸàŸäÿ™ ŸàŸÇÿ∑ÿ± - ÿßŸÑÿ®ÿ≠ÿ´ ÿßŸÑŸÜŸàÿπŸä', items: ['ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ÿßŸÑÿÆÿ®ÿ±ÿßÿ° ÿßŸÑÿ∑ÿ®ŸäŸäŸÜ ŸàÿßŸÑÿßÿ≥ÿ™ÿ¥ÿßÿ±ŸäŸäŸÜ', 'ŸÖÿ¨ÿßŸÑÿ≥ ÿßÿ≥ÿ™ÿ¥ÿßÿ±Ÿäÿ© ŸÑŸÑÿ£ÿ∑ÿ®ÿßÿ°', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿä ŸàÿßŸÑÿ≥Ÿäÿßÿ≥ÿßÿ™'] },
            { name: 'ŸÖÿµÿ± - ÿ±ÿ§Ÿâ ŸÖÿ™ÿπŸÖŸÇÿ©', items: ['ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ÿ£ÿ≥ÿßÿ™ÿ∞ÿ© ÿßŸÑÿ¨ÿßŸÖÿπÿßÿ™ ŸàÿßŸÑÿßÿ≥ÿ™ÿ¥ÿßÿ±ŸäŸäŸÜ', 'ŸÖÿ¨ŸÖŸàÿπÿßÿ™ ŸÜŸÇÿßÿ¥ ŸÖÿπ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑŸÖÿ™ÿÆÿµÿµŸäŸÜ', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÖŸÖÿßÿ±ÿ≥ÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ© ÿßŸÑÿ•ÿ´ŸÜŸàÿ∫ÿ±ÿßŸÅŸäÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ Ÿàÿ¨Ÿáÿßÿ™ ŸÜÿ∏ÿ± ÿßŸÑŸÖÿ±ÿ∂Ÿâ ÿßŸÑÿ´ŸÇÿßŸÅŸäÿ©'] },
            { name: 'ÿßŸÑŸÖÿ∫ÿ±ÿ® ŸàÿßŸÑÿ¨ÿ≤ÿßÿ¶ÿ± Ÿàÿ™ŸàŸÜÿ≥ - ÿßŸÑÿ®ÿ≠ÿ´ ÿßŸÑŸÜŸàÿπŸä', items: ['ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ÿßŸÑÿÆÿ®ÿ±ÿßÿ° ÿßŸÑÿ∑ÿ®ŸäŸäŸÜ ŸÅŸä ÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑŸÜÿ∏ŸÖ ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑŸÖŸÇÿßÿ±ŸÜÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ≥ŸäÿßŸÇ ÿßŸÑÿ´ŸÇÿßŸÅŸä ŸàÿßŸÑÿßÿ¨ÿ™ŸÖÿßÿπŸä'] },
            { name: 'ÿ•Ÿäÿ±ÿßŸÜ - ÿ±ÿ§Ÿâ ÿßŸÑÿÆÿ®ÿ±ÿßÿ°', items: ['ŸÖŸÇÿßÿ®ŸÑÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸàÿßŸÑÿ®ÿßÿ≠ÿ´ŸäŸÜ ÿßŸÑÿ•Ÿäÿ±ÿßŸÜŸäŸäŸÜ', 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑÿ≥ŸàŸÇ ŸàÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿä', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ™ÿµŸÜŸäÿπ ÿßŸÑŸÖÿ≠ŸÑŸä ŸàÿßŸÑÿßÿ®ÿ™ŸÉÿßÿ±'] },
          ],
          deliverables: 'ÿßŸÑŸÖÿÆÿ±ÿ¨ÿßÿ™: ÿ™ŸÇÿßÿ±Ÿäÿ± ÿßŸÑÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖŸàÿ∂ŸàÿπŸäÿå ÿ±ÿ§Ÿâ ÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿäÿå ŸÖŸÑÿÆÿµÿßÿ™ ÿ•ÿ¨ŸÖÿßÿπ ÿßŸÑÿÆÿ®ÿ±ÿßÿ°ÿå ÿ™ŸàÿµŸäÿßÿ™ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ŸÑŸÑŸàÿµŸàŸÑ ŸÑŸÑÿ≥ŸàŸÇÿå ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿßÿ™ ÿßŸÑÿ™ŸÅÿßÿπŸÑ ŸÖÿπ KOLÿå ÿ™ŸÇŸäŸäŸÖÿßÿ™ ÿßŸÑÿßÿ≠ÿ™Ÿäÿßÿ¨ÿßÿ™ ÿ∫Ÿäÿ± ÿßŸÑŸÖŸÑÿ®ÿßÿ©',
        },
      ],
      serviceSecondaryAr: [
        {
          title: 'ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ÿßŸÑŸàÿµŸàŸÑ ŸÑŸÑÿ≥ŸàŸÇ ŸàÿØÿπŸÖ ÿßŸÑÿßŸÇÿ™ÿµÿßÿØ ÿßŸÑÿµÿ≠Ÿä',
          intro: 'ÿßŸÑÿßÿ≥ÿ™ŸÅÿßÿØÿ© ŸÖŸÜ ÿ±ÿ§Ÿâ ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑÿπŸÖŸäŸÇÿ© ŸÑÿØÿπŸÖ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿßÿ™ ÿßŸÑŸàÿµŸàŸÑ ŸÑŸÑÿ≥ŸàŸÇ ŸàÿßŸÑÿ™ÿ≥ÿπŸäÿ± ŸàÿßŸÑÿ≥ÿØÿßÿØ ÿπÿ®ÿ± ÿ£ÿ≥ŸàÿßŸÇ ÿßŸÑÿÆŸÑŸäÿ¨ ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑.',
          regions: [
            { name: 'ÿØŸàŸÑ ÿßŸÑÿÆŸÑŸäÿ¨ ÿßŸÑÿπÿ±ÿ®Ÿä', items: ['ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖÿ¥ŸáÿØ ÿßŸÑÿ™ŸÜÿ∏ŸäŸÖŸä ŸàÿßŸÑÿ™ÿ≥ÿπŸäÿ± (SFDAÿå DHAÿå MOH)', 'ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ÿßŸÑŸÖŸÜÿßŸÇÿµÿßÿ™ ÿßŸÑÿ≠ŸÉŸàŸÖŸäÿ© ŸàÿßŸÑŸàÿµŸàŸÑ ŸÑŸÇŸàÿßÿ¶ŸÖ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™', 'ÿ±ÿ§Ÿâ ÿ£ÿµÿ≠ÿßÿ® ÿßŸÑŸÖÿµŸÑÿ≠ÿ© ÿßŸÑÿ≠ŸÉŸàŸÖŸäŸäŸÜ', 'ÿ™ÿ∑ŸàŸäÿ± ÿπÿ±ÿ∂ ÿßŸÑŸÇŸäŸÖÿ© ŸàÿßŸÑÿ±ÿ≥ÿßÿ¶ŸÑ ÿßŸÑÿ™ÿ≥ŸàŸäŸÇŸäÿ©'] },
            { name: 'ŸÖÿµÿ± Ÿàÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß', items: ['ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ÿßŸÑÿ™ÿ≥ÿπŸäÿ± ŸàÿßŸÑÿ≥ÿØÿßÿØ', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ™ÿ£ŸÖŸäŸÜ ÿßŸÑÿµÿ≠Ÿä ŸàÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ', 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿßŸÇÿ™ÿµÿßÿØ ÿßŸÑÿµÿ≠Ÿä ŸàÿßŸÑŸÜÿ™ÿßÿ¶ÿ¨ (HEOR)'] },
          ],
          note: 'ÿÆÿØŸÖÿßÿ™ŸÜÿß ŸÅŸä ÿßŸÑŸàÿµŸàŸÑ ŸÑŸÑÿ≥ŸàŸÇ ŸÇÿßÿ¶ŸÖÿ© ÿπŸÑŸâ ÿßŸÑÿ£ÿ®ÿ≠ÿßÿ´ÿå ÿ®ÿßÿ≥ÿ™ÿÆÿØÿßŸÖ ÿ±ÿ§Ÿâ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ°ÿå ÿßŸÑÿ¨Ÿáÿßÿ™ ÿßŸÑÿØÿßŸÅÿπÿ©ÿå Ÿàÿ£ÿµÿ≠ÿßÿ® ÿßŸÑŸÖÿµŸÑÿ≠ÿ© ÿßŸÑŸÖÿ¨ŸÖÿπÿ© ŸÖŸÜ ÿÆŸÑÿßŸÑ ŸÇÿØÿ±ÿßÿ™ŸÜÿß ÿßŸÑÿ£ÿ≥ÿßÿ≥Ÿäÿ© ŸÅŸä ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ.',
        },
        {
          title: 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑÿ¨ÿØŸàŸâ ŸÑŸÑÿ™ÿ¨ÿßÿ±ÿ® ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿäÿ© ŸàŸÖÿπŸÑŸàŸÖÿßÿ™ ÿßŸÑŸÖŸàÿßŸÇÿπ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©',
          intro: 'ÿØÿπŸÖ ÿßŸÑÿ™ÿ∑ŸàŸäÿ± ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿä ÿ®ÿ±ÿ§Ÿâ ÿ®ÿ≠ÿ´Ÿäÿ© ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ÿ≠ŸàŸÑ ÿ¨ÿØŸàŸâ ÿßŸÑÿ™ÿ¨ÿßÿ±ÿ®ÿå ÿßÿÆÿ™Ÿäÿßÿ± ÿßŸÑŸÖŸàÿßŸÇÿπÿå Ÿàÿ¥ÿ®ŸÉÿßÿ™ ÿßŸÑÿ®ÿßÿ≠ÿ´ŸäŸÜ.',
          regions: [
            { name: 'ÿÆÿØŸÖÿßÿ™ ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ™ÿ¨ÿßÿ±ÿ® ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿäÿ©', items: ['ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑÿ¨ÿØŸàŸâ Ÿàÿ™ÿ≠ÿØŸäÿØ ÿßŸÑŸÖŸàÿßŸÇÿπ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ© ŸÅŸä ÿßŸÑÿÆŸÑŸäÿ¨ ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑', 'ÿ±ÿ≥ŸÖ ÿÆÿ±ÿßÿ¶ÿ∑ ÿßŸÑÿ®ÿßÿ≠ÿ´ŸäŸÜ Ÿàÿ™ÿ≠ÿØŸäÿØ KOL', 'ÿ±ÿ§Ÿâ ÿ™Ÿàÿ∏ŸäŸÅ ÿßŸÑŸÖÿ±ÿ∂Ÿâ Ÿàÿ™ÿ≠ÿ≥ŸäŸÜ ÿßŸÑÿ®ÿ±Ÿàÿ™ŸàŸÉŸàŸÑ', 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖÿ¥ŸáÿØ ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿä ŸÑŸÑÿ™ÿ¨ÿßÿ±ÿ®', 'ÿ™ŸÇŸäŸäŸÖ ÿ£ÿØÿßÿ° ŸàŸÇÿØÿ±ÿßÿ™ ÿßŸÑŸÖŸàÿßŸÇÿπ'] },
          ],
          note: 'ÿ™ÿ≥ÿ™ŸÅŸäÿØ ÿÆÿØŸÖÿßÿ™ ÿßŸÑÿ™ÿ¨ÿßÿ±ÿ® ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿäÿ© ŸÖŸÜ ÿ¥ÿ®ŸÉÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑŸàÿßÿ≥ÿπÿ© ŸàŸÖÿπÿ±ŸÅÿ™ŸÜÿß ÿ®ÿßŸÑŸÜÿ∏ÿßŸÖ ÿßŸÑÿµÿ≠Ÿä ŸÑÿØÿπŸÖ ÿ®ÿ±ÿßŸÖÿ¨ ÿßŸÑÿ™ÿ∑ŸàŸäÿ± ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿä ÿßŸÑÿÆÿßÿµÿ© ÿ®ŸÉ.',
        },
      ],
      items: [
        {
          title: 'ÿßŸÑŸàÿµŸàŸÑ ÿ•ŸÑŸâ ÿßŸÑÿ≥ŸàŸÇ ŸàÿßŸÑÿ™ÿ≥ÿπŸäÿ±',
          description: 'ÿ™ŸÜŸÇŸÑ ŸÅŸä ŸÖÿ¥ŸáÿØ ÿßŸÑÿ™ÿπŸàŸäÿ∂ÿßÿ™ ÿßŸÑŸÖÿπŸÇÿØ ÿ®ÿßÿ≥ÿ™ÿÆÿØÿßŸÖ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿßÿ™ ÿ™ÿ≥ÿπŸäÿ± ŸÇÿßÿ¶ŸÖÿ© ÿπŸÑŸâ ÿßŸÑÿ£ÿØŸÑÿ© Ÿàÿ£ÿ∑ÿ± ÿ•ÿ¥ÿ±ÿßŸÉ ÿßŸÑÿØÿßŸÅÿπŸäŸÜ.',
        },
        {
          title: 'ÿßŸÑÿßÿ≥ÿ™ÿÆÿ®ÿßÿ±ÿßÿ™ ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿäÿ©',
          description: 'ÿßÿ®ŸÇ ŸÅŸä ÿßŸÑŸÖŸÇÿØŸÖÿ© ŸÖÿπ ÿßŸÑŸÖÿ±ÿßŸÇÿ®ÿ© ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿäÿ© ŸÅŸä ÿßŸÑŸàŸÇÿ™ ÿßŸÑŸÅÿπŸÑŸä Ÿàÿ™ÿ≠ŸÑŸäŸÑ ÿÆÿ∑ ÿßŸÑÿ£ŸÜÿßÿ®Ÿäÿ® Ÿàÿ±ÿ§Ÿâ ÿßŸÑŸÖŸàŸÇÿπ ÿßŸÑÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä.',
        },
      ],
    },
    insights: {
      title: 'ÿ£ÿ≠ÿØÿ´ ÿßŸÑÿ±ÿ§Ÿâ',
      subtitle: 'ÿßŸÑŸÇŸäÿßÿØÿ© ÿßŸÑŸÅŸÉÿ±Ÿäÿ© ŸàŸàÿ¨Ÿáÿßÿ™ ŸÜÿ∏ÿ± ÿßŸÑÿ®ÿ≠ÿ´ ŸÖŸÜ ŸÅÿ±ŸäŸÇŸÜÿß ÿßŸÑÿπÿßŸÑŸÖŸä',
      readMore: 'ÿßŸÇÿ±ÿ£ ÿßŸÑŸÖŸÇÿßŸÑ',
      items: [
        {
          category: 'ÿßŸÑŸàÿµŸàŸÑ ÿ•ŸÑŸâ ÿßŸÑÿ≥ŸàŸÇ',
          title: 'ŸÖÿ≥ÿ™ŸÇÿ®ŸÑ ÿßÿ™ŸÅÿßŸÇŸäÿßÿ™ ÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑŸÇÿßÿ¶ŸÖÿ© ÿπŸÑŸâ ÿßŸÑŸÇŸäŸÖÿ© ŸÅŸä ÿ£Ÿàÿ±Ÿàÿ®ÿß',
          excerpt: 'ŸÉŸäŸÅ ÿ™ÿπŸäÿØ ŸÜŸÖÿßÿ∞ÿ¨ ÿßŸÑÿ™ÿπÿßŸÇÿØ ÿßŸÑŸÖÿ®ÿ™ŸÉÿ±ÿ© ÿ™ÿ¥ŸÉŸäŸÑ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿßÿ™ ÿßŸÑÿ™ÿ≥ÿπŸäÿ± ŸàÿßŸÑŸàÿµŸàŸÑ ÿßŸÑÿµŸäÿØŸÑÿßŸÜŸä ÿπÿ®ÿ± ÿßŸÑÿ£ÿ≥ŸàÿßŸÇ ÿßŸÑÿ£Ÿàÿ±Ÿàÿ®Ÿäÿ© ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿäÿ©.',
          date: 'ÿ™ŸÇÿ±Ÿäÿ± ÿßŸÑÿ±ÿ®ÿπ ÿßŸÑÿ±ÿßÿ®ÿπ 2024',
        },
        {
          category: 'ÿßŸÑÿµÿ≠ÿ© ÿßŸÑÿ±ŸÇŸÖŸäÿ©',
          title: 'ÿßŸÉÿ™ÿ¥ÿßŸÅ ÿßŸÑÿ£ÿØŸàŸäÿ© ÿ®ÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿßÿµÿ∑ŸÜÿßÿπŸä: ÿ™ÿØÿßÿπŸäÿßÿ™ ÿßŸÑÿ≥ŸàŸÇ',
          excerpt: 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ™ÿ≠ŸàŸÑ ÿßŸÑŸÖÿ¥ŸáÿØ ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿä ÿ®ŸäŸÜŸÖÿß Ÿäÿ≠ŸàŸÑ ÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿßÿµÿ∑ŸÜÿßÿπŸä ÿßŸÑÿ®ÿ≠ÿ´ ŸàÿßŸÑÿ™ÿ∑ŸàŸäÿ± ÿßŸÑÿµŸäÿØŸÑÿßŸÜŸä ŸàŸàŸÇÿ™ ÿßŸÑŸàÿµŸàŸÑ ÿ•ŸÑŸâ ÿßŸÑÿ≥ŸàŸÇ.',
          date: 'ŸÖŸàÿ¨ÿ≤ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä',
        },
        {
          category: 'ÿßŸÑÿ£Ÿàÿ±ÿßŸÖ',
          title: 'ÿØŸäŸÜÿßŸÖŸäŸÉŸäÿßÿ™ ÿ≥ŸàŸÇ ÿßŸÑÿ∑ÿ® ÿßŸÑÿØŸÇŸäŸÇ 2025',
          excerpt: 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ¥ÿßŸÖŸÑ ŸÑŸÑÿπŸÑÿßÿ¨ÿßÿ™ ÿßŸÑŸÖŸàÿ¨Ÿáÿ© ÿ®ÿßŸÑŸÖÿ§ÿ¥ÿ±ÿßÿ™ ÿßŸÑÿ≠ŸäŸàŸäÿ© ŸàŸÜŸÖŸàÿ∞ÿ¨ ÿπŸÑÿßÿ¨ ÿßŸÑÿ£Ÿàÿ±ÿßŸÖ ÿßŸÑŸÖÿ™ÿ∑Ÿàÿ±.',
          date: 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿµŸÜÿßÿπÿ©',
        },
      ],
    },
    blog: {
      title: 'ÿ£ÿ≠ÿØÿ´ ÿßŸÑÿ±ÿ§Ÿâ',
      subtitle: 'ÿßŸÑŸÇŸäÿßÿØÿ© ÿßŸÑŸÅŸÉÿ±Ÿäÿ© ŸàŸàÿ¨Ÿáÿßÿ™ ŸÜÿ∏ÿ± ÿßŸÑÿ®ÿ≠ÿ´ ŸÖŸÜ ŸÅÿ±ŸäŸÇŸÜÿß ÿßŸÑÿπÿßŸÑŸÖŸä',
      readMore: 'ÿßŸÇÿ±ÿ£ ÿßŸÑŸÖŸÇÿßŸÑ',
      readMoreArticles: 'ÿßŸÇÿ±ÿ£ ÿßŸÑŸÖÿ≤ŸäÿØ ŸÖŸÜ ÿßŸÑŸÖŸÇÿßŸÑÿßÿ™',
      filterAllTopics: 'ÿ¨ŸÖŸäÿπ ÿßŸÑŸÖŸàÿßÿ∂Ÿäÿπ',
      filterAllCountries: 'ÿ¨ŸÖŸäÿπ ÿßŸÑÿ®ŸÑÿØÿßŸÜ',
      filterByTopic: 'ÿßŸÑŸÖŸàÿ∂Ÿàÿπ',
      filterByCountry: 'ÿßŸÑÿ®ŸÑÿØ',
      items: [
        { category: 'ÿßŸÑŸàÿµŸàŸÑ ÿ•ŸÑŸâ ÿßŸÑÿ≥ŸàŸÇ', country: 'ÿ£Ÿàÿ±Ÿàÿ®ÿß', title: 'ŸÖÿ≥ÿ™ŸÇÿ®ŸÑ ÿßÿ™ŸÅÿßŸÇŸäÿßÿ™ ÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑŸÇÿßÿ¶ŸÖÿ© ÿπŸÑŸâ ÿßŸÑŸÇŸäŸÖÿ© ŸÅŸä ÿ£Ÿàÿ±Ÿàÿ®ÿß', excerpt: 'ŸÉŸäŸÅ ÿ™ÿπŸäÿØ ŸÜŸÖÿßÿ∞ÿ¨ ÿßŸÑÿ™ÿπÿßŸÇÿØ ÿßŸÑŸÖÿ®ÿ™ŸÉÿ±ÿ© ÿ™ÿ¥ŸÉŸäŸÑ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿßÿ™ ÿßŸÑÿ™ÿ≥ÿπŸäÿ± ŸàÿßŸÑŸàÿµŸàŸÑ ÿßŸÑÿµŸäÿØŸÑÿßŸÜŸä ÿπÿ®ÿ± ÿßŸÑÿ£ÿ≥ŸàÿßŸÇ ÿßŸÑÿ£Ÿàÿ±Ÿàÿ®Ÿäÿ© ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿäÿ©.', date: 'ÿ™ŸÇÿ±Ÿäÿ± ÿßŸÑÿ±ÿ®ÿπ ÿßŸÑÿ±ÿßÿ®ÿπ 2024' },
        { category: 'ÿßŸÑÿµÿ≠ÿ© ÿßŸÑÿ±ŸÇŸÖŸäÿ©', country: 'ÿßŸÑŸàŸÑÿßŸäÿßÿ™ ÿßŸÑŸÖÿ™ÿ≠ÿØÿ©', title: 'ÿßŸÉÿ™ÿ¥ÿßŸÅ ÿßŸÑÿ£ÿØŸàŸäÿ© ÿ®ÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿßÿµÿ∑ŸÜÿßÿπŸä: ÿ™ÿØÿßÿπŸäÿßÿ™ ÿßŸÑÿ≥ŸàŸÇ', excerpt: 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ™ÿ≠ŸàŸÑ ÿßŸÑŸÖÿ¥ŸáÿØ ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿä ÿ®ŸäŸÜŸÖÿß Ÿäÿ≠ŸàŸÑ ÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿßÿµÿ∑ŸÜÿßÿπŸä ÿßŸÑÿ®ÿ≠ÿ´ ŸàÿßŸÑÿ™ÿ∑ŸàŸäÿ± ÿßŸÑÿµŸäÿØŸÑÿßŸÜŸä ŸàŸàŸÇÿ™ ÿßŸÑŸàÿµŸàŸÑ ÿ•ŸÑŸâ ÿßŸÑÿ≥ŸàŸÇ.', date: 'ŸÖŸàÿ¨ÿ≤ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä' },
        { category: 'ÿßŸÑÿ£Ÿàÿ±ÿßŸÖ', country: 'ÿßŸÑŸÖŸÖŸÑŸÉÿ© ÿßŸÑŸÖÿ™ÿ≠ÿØÿ©', title: 'ÿØŸäŸÜÿßŸÖŸäŸÉŸäÿßÿ™ ÿ≥ŸàŸÇ ÿßŸÑÿ∑ÿ® ÿßŸÑÿØŸÇŸäŸÇ 2025', excerpt: 'ÿ™ÿ≠ŸÑŸäŸÑ ÿ¥ÿßŸÖŸÑ ŸÑŸÑÿπŸÑÿßÿ¨ÿßÿ™ ÿßŸÑŸÖŸàÿ¨Ÿáÿ© ÿ®ÿßŸÑŸÖÿ§ÿ¥ÿ±ÿßÿ™ ÿßŸÑÿ≠ŸäŸàŸäÿ© ŸàŸÜŸÖŸàÿ∞ÿ¨ ÿπŸÑÿßÿ¨ ÿßŸÑÿ£Ÿàÿ±ÿßŸÖ ÿßŸÑŸÖÿ™ÿ∑Ÿàÿ±.', date: 'ÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿµŸÜÿßÿπÿ©' },
      ],
    },
    stats: {
      title: 'ÿßŸÑÿ™ÿ£ÿ´Ÿäÿ± ÿßŸÑÿπÿßŸÑŸÖŸä',
      items: [
        { value: '+50', label: 'ÿØŸàŸÑÿ© ŸÖÿ∫ÿ∑ÿßÿ©' },
        { value: '+10', label: 'ÿ¥ÿ±ŸÉÿßÿ° ŸÜÿ¨ÿßÿ≠' },
        { value: '+120', label: 'ŸÖÿ¥ÿ±Ÿàÿπ ŸÖŸÜÿ¨ÿ≤' },
        { value: '+15', label: 'ÿ≥ŸÜÿ© ÿÆÿ®ÿ±ÿ©' },
      ],
    },
    testimonials: {
      title: 'ÿ¢ÿ±ÿßÿ° ÿßŸÑÿπŸÖŸÑÿßÿ°',
      subtitle: 'ŸÖŸàÿ´ŸàŸÇ ÿ®Ÿá ŸÖŸÜ ŸÇÿ®ŸÑ ÿ¥ÿ±ŸÉÿßÿ™ ÿßŸÑÿ£ÿØŸàŸäÿ© ŸàÿßŸÑÿ™ŸÉŸÜŸàŸÑŸàÿ¨Ÿäÿß ÿßŸÑÿ≠ŸäŸàŸäÿ© ÿßŸÑÿ±ÿßÿ¶ÿØÿ© ŸÅŸä ÿ¨ŸÖŸäÿπ ÿ£ŸÜÿ≠ÿßÿ° ÿßŸÑÿπÿßŸÑŸÖ',
      items: [
        { quote: 'ÿ≠ŸàŸëŸÑÿ™ BioNixus ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ŸàÿµŸàŸÑŸÜÿß ÿ•ŸÑŸâ ÿßŸÑÿ≥ŸàŸÇ ÿ®ÿ±ÿ§Ÿâ ÿØŸÇŸäŸÇÿ© ŸàŸÇÿßÿ®ŸÑÿ© ŸÑŸÑÿ™ÿ∑ÿ®ŸäŸÇ. ŸàŸÉÿßŸÜÿ™ Ÿàÿ¨Ÿáÿ© ŸÜÿ∏ÿ±ŸáŸÖ ŸÑÿß ÿ™ŸÇÿØÿ± ÿ®ÿ´ŸÖŸÜ.', author: 'Dr. Sarah Mitchell', role: 'VP Market Access', company: 'Global Pharma Inc.' },
        { quote: 'ŸÑŸÇÿØ ÿ™ÿ¨ÿßŸàÿ≤ ÿπŸÖŸÇ ÿßŸÑÿ∞ŸÉÿßÿ° ÿßŸÑÿ™ŸÜÿßŸÅÿ≥Ÿä Ÿàÿ≥ÿ±ÿπÿ© ÿßŸÑÿ™ÿ≥ŸÑŸäŸÖ ÿ™ŸàŸÇÿπÿßÿ™ŸÜÿß ÿ®ÿ¥ŸÉŸÑ ŸÉÿ®Ÿäÿ±. ÿ•ŸÜŸáŸÖ ÿ¥ÿ±ŸäŸÉ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä ÿ≠ŸÇŸäŸÇŸä ÿ®ÿßŸÖÿ™Ÿäÿßÿ≤.', author: 'Michael Chen', role: 'Chief Strategy Officer', company: 'BioTech Company' },
        { quote: 'ÿ£ÿ´ÿ± ÿ±ÿ≥ŸÖ ÿÆÿ±ÿßÿ¶ÿ∑ KOL Ÿàÿ£ÿ®ÿ≠ÿßÿ´ ÿ±ÿ≠ŸÑÿ© ÿßŸÑŸÖÿ±Ÿäÿ∂ ÿ®ÿ¥ŸÉŸÑ ŸÖÿ®ÿßÿ¥ÿ± ÿπŸÑŸâ ŸÜÿ¨ÿßÿ≠ ÿ•ÿ∑ŸÑÿßŸÇŸÜÿß ŸÅŸä ÿ´ŸÑÿßÿ´ÿ© ÿ£ÿ≥ŸàÿßŸÇ ÿ£Ÿàÿ±Ÿàÿ®Ÿäÿ© ÿ±ÿ¶Ÿäÿ≥Ÿäÿ©.', author: 'Dr. Elena Rodriguez', role: 'Commercial Director', company: 'Leading Pharma Company' },
      ],
    },
    contact: {
      title: 'ŸÑŸÜÿ™ŸàÿßÿµŸÑ',
      subtitle: 'ŸáŸÑ ÿ£ŸÜÿ™ ŸÖÿ≥ÿ™ÿπÿØ ŸÑÿ™ÿ≠ŸàŸäŸÑ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ÿ≥ŸàŸÇ ÿßŸÑÿ±ÿπÿßŸäÿ© ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑÿÆÿßÿµÿ© ÿ®ŸÉÿü ŸÅÿ±ŸäŸÇ ÿÆÿ®ÿ±ÿßÿ¶ŸÜÿß ŸáŸÜÿß ŸÑŸÑŸÖÿ≥ÿßÿπÿØÿ©.',
      cta: 'ÿ≠ÿØÿØ ŸÖŸàÿπÿØ ÿßÿ≥ÿ™ÿ¥ÿßÿ±ÿ©',
      ctaSecondary: 'ÿßÿ≥ÿ™ŸÉÿ¥ŸÅ ÿÆÿØŸÖÿßÿ™ŸÜÿß',
      email: 'admin@bionixus.com',
      headquarters: 'Wyoming, USA',
      emailLabel: 'ÿßŸÑÿ®ÿ±ŸäÿØ ÿßŸÑÿ•ŸÑŸÉÿ™ÿ±ŸàŸÜŸä',
      headquartersLabel: 'ÿßŸÑŸÖŸÇÿ± ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿä',
      phoneLabel: 'ÿßŸÑŸáÿßÿ™ŸÅ',
      formTitle: 'ÿ∑ŸÑÿ® ÿπÿ±ÿ∂',
      firstName: 'ÿßŸÑÿßÿ≥ŸÖ ÿßŸÑÿ£ŸàŸÑ',
      lastName: 'ÿßÿ≥ŸÖ ÿßŸÑÿπÿßÿ¶ŸÑÿ©',
      workEmail: 'ÿßŸÑÿ®ÿ±ŸäÿØ ÿßŸÑÿ•ŸÑŸÉÿ™ÿ±ŸàŸÜŸä ŸÑŸÑÿπŸÖŸÑ',
      company: 'ÿßŸÑÿ¥ÿ±ŸÉÿ©',
      message: 'ÿßŸÑÿ±ÿ≥ÿßŸÑÿ©',
      submitButton: 'ÿ•ÿ±ÿ≥ÿßŸÑ',
      firstNamePlaceholder: 'ÿ£ÿ≠ŸÖÿØ',
      lastNamePlaceholder: 'ŸÖÿ≠ŸÖÿØ',
      workEmailPlaceholder: 'ahmed@company.com',
      companyPlaceholder: 'ÿ¥ÿ±ŸÉÿ™ŸÉ',
      messagePlaceholder: 'ÿµŸÅ ÿßÿ≠ÿ™Ÿäÿßÿ¨ÿßÿ™ŸÉ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©...',
      successTitle: 'ÿ¥ŸÉÿ±ÿßŸã ŸÑŸÉ!',
      successBody: 'ÿ™ŸÖ ÿ•ÿ±ÿ≥ÿßŸÑ ÿßÿ≥ÿ™ŸÅÿ≥ÿßÿ±ŸÉ ÿ®ŸÜÿ¨ÿßÿ≠. ÿ≥Ÿäÿ™ŸàÿßÿµŸÑ ŸÖÿπŸÉ ŸÅÿ±ŸäŸÇŸÜÿß ŸÇÿ±Ÿäÿ®ÿßŸã.',
      successCaseStudiesText: 'ÿØÿ±ÿßÿ≥ÿßÿ™ ÿßŸÑÿ≠ÿßŸÑÿ©',
      successMethodologyText: 'ÿßŸÑŸÖŸÜŸáÿ¨Ÿäÿ©',
      successFollowUpIntro: 'ÿßÿ≥ÿ™ŸÉÿ¥ŸÅ ',
      successFollowUpBetween: ' ÿ£Ÿà ',
      successFollowUpEnd: ' ŸÅŸä ÿ∫ÿ∂ŸàŸÜ ÿ∞ŸÑŸÉ.',
      validation: {
        firstName: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ÿ•ÿØÿÆÿßŸÑ ÿßÿ≥ŸÖŸÉ ÿßŸÑÿ£ŸàŸÑ',
        lastName: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ÿ•ÿØÿÆÿßŸÑ ÿßÿ≥ŸÖ ÿßŸÑÿπÿßÿ¶ŸÑÿ©',
        workEmail: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ÿ•ÿØÿÆÿßŸÑ ÿ®ÿ±ŸäÿØ ÿ•ŸÑŸÉÿ™ÿ±ŸàŸÜŸä ÿπŸÖŸÑ ÿµÿßŸÑÿ≠',
        company: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ÿ•ÿØÿÆÿßŸÑ ÿßÿ≥ŸÖ ÿ¥ÿ±ŸÉÿ™ŸÉ',
        message: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ŸàÿµŸÅ ŸÉŸäŸÅ ŸäŸÖŸÉŸÜŸÜÿß ŸÖÿ≥ÿßÿπÿØÿ™ŸÉ',
        privacy: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ŸÇÿ®ŸàŸÑ ÿ≥Ÿäÿßÿ≥ÿ© ÿßŸÑÿÆÿµŸàÿµŸäÿ©',
        emailFormat: 'ÿßŸÑÿ±ÿ¨ÿßÿ° ÿ•ÿØÿÆÿßŸÑ ÿπŸÜŸàÿßŸÜ ÿ®ÿ±ŸäÿØ ÿ•ŸÑŸÉÿ™ÿ±ŸàŸÜŸä ÿµÿßŸÑÿ≠',
        success: 'ÿ™ŸÖ ÿ•ÿ±ÿ≥ÿßŸÑ ÿßÿ≥ÿ™ŸÅÿ≥ÿßÿ±ŸÉ ÿ®ŸÜÿ¨ÿßÿ≠!',
        error: 'ÿ≠ÿØÿ´ ÿÆÿ∑ÿ£. Ÿäÿ±ÿ¨Ÿâ ÿßŸÑŸÖÿ≠ÿßŸàŸÑÿ© ŸÖÿ±ÿ© ÿ£ÿÆÿ±Ÿâ ÿ£Ÿà ÿßŸÑÿßÿ™ÿµÿßŸÑ ÿ®ŸÜÿß ÿπÿ®ÿ± ÿßŸÑÿ®ÿ±ŸäÿØ ÿßŸÑÿ•ŸÑŸÉÿ™ÿ±ŸàŸÜŸä.',
      },
    },
    localePrompt: {
      title: 'ÿ£ŸÜÿ™ ÿ™ŸÅÿ™ÿ≠ ŸÖŸÜ {region}.',
      question: 'ŸáŸÑ ÿ™ÿ±ŸäÿØ ÿßŸÑÿ™ÿ®ÿØŸäŸÑ ÿ•ŸÑŸâ {language}ÿü',
      yes: 'ŸÜÿπŸÖ',
      no: 'ŸÑÿß',
    },
    footer: {
      tagline: 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑÿµÿ≠Ÿäÿ© | ÿ±ÿ§Ÿâ ÿØŸàÿßÿ¶Ÿäÿ© ÿ£Ÿàÿ±Ÿàÿ®ÿß ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑ Ÿàÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß. ÿ™ŸÇÿØŸäŸÖ ÿ±ÿ§Ÿâ ŸÇÿßÿ¶ŸÖÿ© ÿπŸÑŸâ ÿßŸÑÿ£ÿØŸÑÿ© ŸÑŸÇÿßÿØÿ© ÿßŸÑÿµŸÜÿßÿπÿ© ÿßŸÑÿØŸàÿßÿ¶Ÿäÿ© ŸàÿßŸÑÿ™ŸÉŸÜŸàŸÑŸàÿ¨Ÿäÿß ÿßŸÑÿ≠ŸäŸàŸäÿ© ŸÅŸä ÿ¨ŸÖŸäÿπ ÿ£ŸÜÿ≠ÿßÿ° ÿßŸÑÿπÿßŸÑŸÖ.',
      companyHeading: 'ÿßŸÑÿ¥ÿ±ŸÉÿ©',
      about: 'ŸÖŸÜ ŸÜÿ≠ŸÜ',
      services: 'ÿßŸÑÿÆÿØŸÖÿßÿ™',
      insights: 'ÿßŸÑÿ±ÿ§Ÿâ',
      careers: 'ÿßŸÑŸàÿ∏ÿßÿ¶ŸÅ',
      clientsPortal: 'ÿ®Ÿàÿßÿ®ÿ© ÿßŸÑÿπŸÖŸÑÿßÿ°',
      caseStudies: 'ÿ≥ÿßÿ®ŸÇÿ© ÿßŸÑÿ£ÿπŸÖÿßŸÑ',
      contactHeading: 'ÿßÿ™ÿµŸÑ ÿ®ŸÜÿß',
      locationUs: 'ŸàÿßŸäŸàŸÖŸÜÿ∫ÿå ÿßŸÑŸàŸÑÿßŸäÿßÿ™ ÿßŸÑŸÖÿ™ÿ≠ÿØÿ©',
      locationUk: 'ŸÑŸÜÿØŸÜÿå ÿßŸÑŸÖŸÖŸÑŸÉÿ© ÿßŸÑŸÖÿ™ÿ≠ÿØÿ©',
      copyright: '¬© 2026 BioNixus. ÿ¨ŸÖŸäÿπ ÿßŸÑÿ≠ŸÇŸàŸÇ ŸÖÿ≠ŸÅŸàÿ∏ÿ©.',
      privacy: 'ÿ≥Ÿäÿßÿ≥ÿ© ÿßŸÑÿÆÿµŸàÿµŸäÿ©',
      terms: 'ÿ¥ÿ±Ÿàÿ∑ ÿßŸÑÿÆÿØŸÖÿ©',
    },
    cookieConsent: {
      message: 'ŸÜÿ≥ÿ™ÿÆÿØŸÖ ŸÖŸÑŸÅÿßÿ™ ÿ™ÿπÿ±ŸäŸÅ ÿßŸÑÿßÿ±ÿ™ÿ®ÿßÿ∑ ŸÑÿ™ÿ≠ÿ≥ŸäŸÜ ÿ™ÿ¨ÿ±ÿ®ÿ™ŸÉ Ÿàÿ™ÿ≠ŸÑŸäŸÑ ÿ≠ÿ±ŸÉÿ© ÿßŸÑŸÖŸàŸÇÿπ. ÿ®ÿßŸÑŸÜŸÇÿ± ÿπŸÑŸâ ŸÇÿ®ŸàŸÑ ŸÅÿ•ŸÜŸÉ ÿ™ŸàÿßŸÅŸÇ ÿπŸÑŸâ ÿßÿ≥ÿ™ÿÆÿØÿßŸÖŸÜÿß ŸÑŸÖŸÑŸÅÿßÿ™ ÿ™ÿπÿ±ŸäŸÅ ÿßŸÑÿßÿ±ÿ™ÿ®ÿßÿ∑ Ÿàÿ≥Ÿäÿßÿ≥ÿ© ÿßŸÑÿÆÿµŸàÿµŸäÿ©.',
      accept: 'ŸÇÿ®ŸàŸÑ',
      decline: 'ÿ±ŸÅÿ∂',
      privacyLink: 'ÿ≥Ÿäÿßÿ≥ÿ© ÿßŸÑÿÆÿµŸàÿµŸäÿ©',
    },
    geographicCoverageAr: {
      title: 'ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑÿµÿ≠Ÿäÿ© ÿπÿ®ÿ± ÿØŸàŸÑ ÿßŸÑÿÆŸÑŸäÿ¨ ŸàÿßŸÑÿ¥ÿ±ŸÇ ÿßŸÑÿ£Ÿàÿ≥ÿ∑',
      countries: [
        {
          name: 'ÿßŸÑŸÖŸÖŸÑŸÉÿ© ÿßŸÑÿπÿ±ÿ®Ÿäÿ© ÿßŸÑÿ≥ÿπŸàÿØŸäÿ© - ŸÖÿ±ŸÉÿ≤ ÿßŸÑÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿØŸàÿßÿ¶Ÿäÿ©',
          featured: true,
          marketSize: 'ÿ£ŸÉÿ®ÿ± ÿ≥ŸàŸÇ ÿØŸàÿßÿ¶Ÿä ŸÅŸä ŸÖŸÜÿ∑ŸÇÿ© ÿßŸÑÿÆŸÑŸäÿ¨',
          sections: [
            { heading: 'ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ¨ÿ∫ÿ±ÿßŸÅŸäÿ©', items: ['ÿßŸÑÿ±Ÿäÿßÿ∂: ŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ Ÿàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ©ÿå ÿßŸÑŸÖÿØŸÜ ÿßŸÑÿ∑ÿ®Ÿäÿ©ÿå ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ', 'ÿ¨ÿØÿ©: ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ©ÿå ÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿßŸÑÿØŸÖÿßŸÖ ŸàÿßŸÑŸÖŸÜÿ∑ŸÇÿ© ÿßŸÑÿ¥ÿ±ŸÇŸäÿ©: ÿßŸÑŸÖÿ¨ŸÖÿπÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ÿßŸÑŸÖÿØŸäŸÜÿ© ÿßŸÑŸÖŸÜŸàÿ±ÿ©ÿå ŸÖŸÉÿ© ÿßŸÑŸÖŸÉÿ±ŸÖÿ©ÿå ÿ£ÿ®Ÿáÿß: ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ•ŸÇŸÑŸäŸÖŸäÿ©'] },
            { heading: 'ÿßŸÑŸÖÿ§ÿ≥ÿ≥ÿßÿ™ ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿäÿ©', items: ['Ÿàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ© - ÿ¥ÿ®ŸÉÿ© ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ≠ŸÉŸàŸÖŸäÿ©', 'ŸÖÿØŸäŸÜÿ© ÿßŸÑŸÖŸÑŸÉ ŸÅŸáÿØ ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ŸÖÿ¨ŸÖÿπ ÿßŸÑŸÖŸÑŸÉ ÿπÿ®ÿØÿßŸÑŸÑŸá ÿßŸÑÿ∑ÿ®Ÿä', 'ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ÿßŸÑŸÖŸÑŸÉ ŸÅŸäÿµŸÑ ÿßŸÑÿ™ÿÆÿµÿµŸä', 'ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ: ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ÿßŸÑŸÖŸÖŸÑŸÉÿ©ÿå ÿ≥ŸÑŸäŸÖÿßŸÜ ÿßŸÑÿ≠ÿ®Ÿäÿ®ÿå ÿØŸÑŸá'] },
            { heading: 'ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©', text: 'ÿßŸÑÿ≥ŸÉÿ±Ÿäÿå ÿßŸÑŸÇŸÑÿ® ŸàÿßŸÑÿ£ŸàÿπŸäÿ© ÿßŸÑÿØŸÖŸàŸäÿ©ÿå ÿßŸÑÿ£Ÿàÿ±ÿßŸÖÿå ÿßŸÑÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑŸÜÿßÿØÿ±ÿ©ÿå ÿ∑ÿ® ÿßŸÑÿ£ÿ∑ŸÅÿßŸÑÿå ÿµÿ≠ÿ© ÿßŸÑŸÖÿ±ÿ£ÿ©' },
            { heading: 'ÿßŸÑÿßŸÖÿ™ÿ´ÿßŸÑ ÿßŸÑÿ™ŸÜÿ∏ŸäŸÖŸä', text: 'ŸÖÿ™ŸàÿßŸÅŸÇ ŸÖÿπ ŸáŸäÿ¶ÿ© ÿßŸÑÿ∫ÿ∞ÿßÿ° ŸàÿßŸÑÿØŸàÿßÿ° ÿßŸÑÿ≥ÿπŸàÿØŸäÿ© (SFDA) ŸàŸàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ©' },
          ],
        },
        {
          name: 'ÿßŸÑÿ•ŸÖÿßÿ±ÿßÿ™ ÿßŸÑÿπÿ±ÿ®Ÿäÿ© ÿßŸÑŸÖÿ™ÿ≠ÿØÿ© - ŸÖÿ±ŸÉÿ≤ ÿßŸÑÿßÿ®ÿ™ŸÉÿßÿ± ÿßŸÑÿµÿ≠Ÿä',
          featured: true,
          marketSize: 'ÿ≥ŸàŸÇ ÿµÿ≠Ÿä ŸÖÿ™ŸÇÿØŸÖ ŸÖÿπ ÿ≥Ÿäÿßÿ≠ÿ© ÿπŸÑÿßÿ¨Ÿäÿ©',
          sections: [
            { heading: 'ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ¨ÿ∫ÿ±ÿßŸÅŸäÿ©', items: ['ÿØÿ®Ÿä: ŸÖÿØŸäŸÜÿ© ÿØÿ®Ÿä ÿßŸÑÿ∑ÿ®Ÿäÿ©ÿå ŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ', 'ÿ£ÿ®Ÿàÿ∏ÿ®Ÿä: ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ŸÉŸÑŸäŸÅŸÑÿßŸÜÿØ ŸÉŸÑŸäŸÜŸÉÿå ŸÖÿØŸäŸÜÿ© ÿßŸÑÿ¥ŸäÿÆ ÿÆŸÑŸäŸÅÿ© ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ÿßŸÑÿ¥ÿßÿ±ŸÇÿ© ŸàÿßŸÑÿ•ŸÖÿßÿ±ÿßÿ™ ÿßŸÑÿ¥ŸÖÿßŸÑŸäÿ©: ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ•ŸÇŸÑŸäŸÖŸäÿ©'] },
            { heading: 'ÿßŸÑŸÖÿ§ÿ≥ÿ≥ÿßÿ™ ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿäÿ©', items: ['ŸáŸäÿ¶ÿ© ÿßŸÑÿµÿ≠ÿ© ÿ®ÿØÿ®Ÿä (DHA)', 'ÿØÿßÿ¶ÿ±ÿ© ÿßŸÑÿµÿ≠ÿ© ÿ£ÿ®Ÿàÿ∏ÿ®Ÿä (DOH)', 'ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ŸÉŸÑŸäŸÅŸÑÿßŸÜÿØ ŸÉŸÑŸäŸÜŸÉ ÿ£ÿ®Ÿàÿ∏ÿ®Ÿä', 'ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ÿßŸÑÿ¨ŸÑŸäŸÑÿ© ÿßŸÑÿ™ÿÆÿµÿµŸä ŸÑŸÑÿ£ÿ∑ŸÅÿßŸÑ', 'ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ: NMCÿå ŸÖŸäÿØŸÉŸäÿ±ÿå ÿ®ÿ±ÿ¨ŸäŸÑ'] },
            { heading: 'ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©', text: 'ÿßŸÑÿ£Ÿàÿ±ÿßŸÖÿå ÿßŸÑŸÇŸÑÿ®ÿå ÿßŸÑÿ¨ÿ±ÿßÿ≠ÿ© ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©ÿå ÿßŸÑÿ∑ÿ® ÿßŸÑÿ™ÿ¨ÿØŸäÿØŸäÿå ÿßŸÑÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑÿßÿ≥ÿ™ŸÇŸÑÿßÿ®Ÿäÿ©' },
          ],
        },
        {
          name: 'ÿßŸÑŸÉŸàŸäÿ™ - ŸÜÿ∏ÿßŸÖ ÿµÿ≠Ÿä ŸÖÿ™ŸÇÿØŸÖ',
          featured: false,
          sections: [
            { heading: 'ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ©', items: ['ŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ Ÿàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ©', 'ÿßŸÑŸÖÿ¨ŸÖÿπÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ© ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ ŸàÿßŸÑÿπŸäÿßÿØÿßÿ™'] },
            { heading: 'ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©', text: 'ÿßŸÑÿ≥ŸÉÿ±Ÿäÿå ÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑŸÇŸÑÿ®ÿå ÿ¨ÿ±ÿßÿ≠ÿ© ÿßŸÑÿ≥ŸÖŸÜÿ©ÿå ÿßŸÑÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑŸÖÿ≤ŸÖŸÜÿ©' },
            { heading: 'ŸÇÿ∑ÿ± - ÿßŸÑÿ™ŸÖŸäÿ≤ ÿßŸÑÿ∑ÿ®Ÿä - ÿßŸÑŸÖÿ§ÿ≥ÿ≥ÿßÿ™ ÿßŸÑÿ±ÿ¶Ÿäÿ≥Ÿäÿ©', items: ['ŸÖÿ§ÿ≥ÿ≥ÿ© ÿ≠ŸÖÿØ ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ÿ≥ÿØÿ±ÿ© ŸÑŸÑÿ∑ÿ®', 'ŸÖÿ≥ÿ™ÿ¥ŸÅŸâ ÿßŸÑÿπŸÖÿßÿØŸä', 'ÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ∑ÿ®Ÿäÿ© ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©'] },
            { heading: 'ŸÇÿ∑ÿ± - ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©', items: ['ÿ∑ÿ® ÿßŸÑÿ£ÿ∑ŸÅÿßŸÑ', 'ÿµÿ≠ÿ© ÿßŸÑŸÖÿ±ÿ£ÿ©', 'ÿßŸÑÿ£Ÿàÿ±ÿßŸÖ', 'ÿßŸÑÿ∑ÿ® ÿßŸÑÿ±Ÿäÿßÿ∂Ÿä'] },
          ],
        },
        {
          name: 'ŸÖÿµÿ± - ÿ£ŸÉÿ®ÿ± ÿ≥ŸàŸÇ ŸÅŸä ÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß',
          featured: true,
          marketSize: '100+ ŸÖŸÑŸäŸàŸÜ ŸÜÿ≥ŸÖÿ©ÿå ÿ≥ŸàŸÇ ÿØŸàÿßÿ¶Ÿä ŸÖÿ™ŸÜÿßŸÖŸä',
          sections: [
            { heading: 'ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ¨ÿ∫ÿ±ÿßŸÅŸäÿ©', items: ['ÿßŸÑŸÇÿßŸáÿ±ÿ© ÿßŸÑŸÉÿ®ÿ±Ÿâ: ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ©ÿå ÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©', 'ÿßŸÑÿ•ÿ≥ŸÉŸÜÿØÿ±Ÿäÿ©: ŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿ¨ÿßŸÖÿπŸäÿ© ŸàÿÆÿßÿµÿ©', 'ÿßŸÑÿØŸÑÿ™ÿß ŸàÿßŸÑÿµÿπŸäÿØ: ŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿ•ŸÇŸÑŸäŸÖŸäÿ©'] },
            { heading: 'ÿßŸÑŸÖÿ§ÿ≥ÿ≥ÿßÿ™ ÿßŸÑÿµÿ≠Ÿäÿ©', items: ['ŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿ¨ÿßŸÖÿπÿ© ÿßŸÑŸÇÿßŸáÿ±ÿ© ŸàÿπŸäŸÜ ÿ¥ŸÖÿ≥', 'ÿßŸÑŸÖÿπŸáÿØ ÿßŸÑŸÇŸàŸÖŸä ŸÑŸÑÿ£Ÿàÿ±ÿßŸÖ', 'ŸÖÿπŸáÿØ ÿßŸÑŸÇŸÑÿ® ÿßŸÑŸÇŸàŸÖŸä', 'ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ: ÿØÿßÿ± ÿßŸÑŸÅÿ§ÿßÿØÿå ÿßŸÑÿ≥ÿπŸàÿØŸä ÿßŸÑÿ£ŸÑŸÖÿßŸÜŸäÿå ŸÉŸÑŸäŸàÿ®ÿßÿ™ÿ±ÿß'] },
            { heading: 'ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©', text: 'ÿßŸÑÿ£Ÿàÿ±ÿßŸÖÿå ÿßŸÑŸÇŸÑÿ® ŸàÿßŸÑÿ£ŸàÿπŸäÿ© ÿßŸÑÿØŸÖŸàŸäÿ©ÿå ÿßŸÑÿ≥ŸÉÿ±Ÿäÿå ÿßŸÑŸÉÿ®ÿØÿå ÿßŸÑÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑŸÖÿπÿØŸäÿ©ÿå ÿµÿ≠ÿ© ÿßŸÑÿ£ŸÖ ŸàÿßŸÑÿ∑ŸÅŸÑ' },
            { heading: 'ÿßŸÑÿßŸÖÿ™ÿ´ÿßŸÑ', text: 'ŸÖÿ™ŸàÿßŸÅŸÇ ŸÖÿπ ŸáŸäÿ¶ÿ© ÿßŸÑÿØŸàÿßÿ° ÿßŸÑŸÖÿµÿ±Ÿäÿ© ŸàŸàÿ≤ÿßÿ±ÿ© ÿßŸÑÿµÿ≠ÿ©' },
          ],
        },
        {
          name: 'ÿßŸÑŸÖÿ∫ÿ±ÿ® - ÿ≥ŸàŸÇ ÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß ÿßŸÑÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿä',
          featured: false,
          sections: [
            { heading: 'ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ¨ÿ∫ÿ±ÿßŸÅŸäÿ©', items: ['ÿßŸÑÿØÿßÿ± ÿßŸÑÿ®Ÿäÿ∂ÿßÿ°: ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© CHUÿå ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿÆÿßÿµ', 'ÿßŸÑÿ±ÿ®ÿßÿ∑: ÿßŸÑŸÖÿ±ÿßŸÉÿ≤ ÿßŸÑÿ∑ÿ®Ÿäÿ© ÿßŸÑÿ≠ŸÉŸàŸÖŸäÿ©', 'ŸÖÿ±ÿßŸÉÿ¥ÿå ŸÅÿßÿ≥ÿå ÿ∑ŸÜÿ¨ÿ©: ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ•ŸÇŸÑŸäŸÖŸäÿ©'] },
            { heading: 'ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑÿ®ÿ≠ÿ´Ÿäÿ©', text: 'ÿßŸÑÿ£Ÿàÿ±ÿßŸÖÿå ÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑŸÇŸÑÿ®ÿå ÿßŸÑÿ≥ŸÉÿ±Ÿäÿå ÿßŸÑÿ£ŸÖÿ±ÿßÿ∂ ÿßŸÑŸÖÿπÿØŸäÿ©' },
          ],
        },
        {
          name: 'ÿßŸÑÿ¨ÿ≤ÿßÿ¶ÿ± - ÿ≥ŸàŸÇ ŸÖÿ™ŸÜÿßŸÖŸä',
          featured: false,
          sections: [
            { heading: 'ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ©', items: ['ÿßŸÑÿ¨ÿ≤ÿßÿ¶ÿ± ÿßŸÑÿπÿßÿµŸÖÿ©ÿå ŸàŸáÿ±ÿßŸÜÿå ŸÇÿ≥ŸÜÿ∑ŸäŸÜÿ©', 'ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ© CHU', 'ÿßŸÑŸÇÿ∑ÿßÿπ ÿßŸÑÿπÿßŸÖ ŸàÿßŸÑÿÆÿßÿµ'] },
            { heading: 'ÿ™ŸàŸÜÿ≥ - ŸÖÿ±ŸÉÿ≤ ÿ∑ÿ®Ÿä ÿ•ŸÇŸÑŸäŸÖŸä - ÿßŸÑÿ™ÿ∫ÿ∑Ÿäÿ©', items: ['ÿ™ŸàŸÜÿ≥ ÿßŸÑÿπÿßÿµŸÖÿ©ÿå ÿµŸÅÿßŸÇÿ≥ÿå ÿ≥Ÿàÿ≥ÿ©', 'ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ¨ÿßŸÖÿπŸäÿ©', 'ÿßŸÑÿπŸäÿßÿØÿßÿ™ ÿßŸÑÿ™ÿÆÿµÿµŸäÿ©'] },
          ],
        },
      ],
    },
    methodologyAr: {
      title: 'ŸÖŸÜŸáÿ¨Ÿäÿ© ÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑÿ≥ŸàŸÇ ÿßŸÑÿµÿ≠Ÿäÿ© ÿßŸÑŸÇÿßÿ¶ŸÖÿ© ÿπŸÑŸâ ÿßŸÑÿ£ÿØŸÑÿ©',
      steps: [
        {
          title: 'ÿßŸÑŸÖÿ±ÿ≠ŸÑÿ© 1: ÿ™ÿµŸÖŸäŸÖ ÿßŸÑÿ®ÿ≠ÿ´ Ÿàÿ™ÿ∑ŸàŸäÿ± ÿßŸÑÿ®ÿ±Ÿàÿ™ŸàŸÉŸàŸÑ',
          items: ['ŸÖŸÜŸáÿ¨Ÿäÿ© ŸÖÿÆÿµÿµÿ© ŸÖÿ™ŸàÿßŸÅŸÇÿ© ŸÖÿπ ÿßŸÑŸÖÿ¨ÿßŸÑ ÿßŸÑÿπŸÑÿßÿ¨Ÿä', 'ÿßŸÑÿßŸÖÿ™ÿ´ÿßŸÑ ÿßŸÑÿ™ŸÜÿ∏ŸäŸÖŸä (SFDAÿå DHAÿå Ÿàÿ≤ÿßÿ±ÿßÿ™ ÿßŸÑÿµÿ≠ÿ© ÿßŸÑÿ•ŸÇŸÑŸäŸÖŸäÿ©)', 'ÿ≠ŸÖÿßŸäÿ© ÿßŸÑÿ®ŸäÿßŸÜÿßÿ™ ŸàÿßŸÑÿÆÿµŸàÿµŸäÿ©', 'ŸÖÿπÿßŸäŸäÿ± ÿßŸÑÿ®ÿ≠ÿ´ ÿßŸÑÿ≥ÿ±Ÿäÿ±Ÿä ÿßŸÑÿØŸàŸÑŸäÿ© (ICH-GCP)', 'ÿ≠ÿ≥ÿßÿ®ÿßÿ™ ÿßŸÑŸÇŸàÿ© ÿßŸÑÿ•ÿ≠ÿµÿßÿ¶Ÿäÿ©', 'ÿßŸÑÿ™ŸÉŸäŸÅ ÿßŸÑÿ´ŸÇÿßŸÅŸä ŸàÿßŸÑŸÑÿ∫ŸàŸä'],
        },
        {
          title: 'ÿßŸÑŸÖÿ±ÿ≠ŸÑÿ© 2: ÿ™Ÿàÿ∏ŸäŸÅ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ŸàÿßŸÑŸÖŸáŸÜŸäŸäŸÜ ÿßŸÑÿµÿ≠ŸäŸäŸÜ',
          subsections: [
            { heading: 'ÿØŸàŸÑ ÿßŸÑÿÆŸÑŸäÿ¨', items: ['ŸÇŸàÿßÿ¶ŸÖ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑŸÖÿπÿ™ŸÖÿØŸäŸÜ ŸÖŸÜ ÿßŸÑŸáŸäÿ¶ÿßÿ™ ÿßŸÑÿµÿ≠Ÿäÿ©', 'ÿ¥ÿ®ŸÉÿßÿ™ ÿßŸÑÿßÿ≥ÿ™ÿ¥ÿßÿ±ŸäŸäŸÜ ŸÅŸä ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ ÿßŸÑÿ≠ŸÉŸàŸÖŸäÿ© ŸàÿßŸÑÿÆÿßÿµÿ©', 'ÿ™ÿ∫ÿ∑Ÿäÿ© ÿßŸÑÿ™ÿÆÿµÿµÿßÿ™ ÿßŸÑŸÖÿ™ÿπÿØÿØÿ© (ÿßŸÑÿ£Ÿàÿ±ÿßŸÖÿå ÿßŸÑŸÇŸÑÿ®ÿå ÿßŸÑÿ∫ÿØÿØ ÿßŸÑÿµŸÖÿßÿ°ÿå ÿ•ŸÑÿÆ)', 'ÿßŸÑÿ™ŸÖÿ´ŸäŸÑ ÿπÿ®ÿ± ŸÖÿ≥ÿ™ŸàŸäÿßÿ™ ÿßŸÑŸÖÿ≥ÿ™ÿ¥ŸÅŸäÿßÿ™ (ÿ£ŸàŸÑŸäÿ©ÿå ÿ´ÿßŸÜŸàŸäÿ©ÿå ÿ´ÿßŸÑÿ´Ÿäÿ©)'] },
            { heading: 'ŸÖÿµÿ± Ÿàÿ¥ŸÖÿßŸÑ ÿ£ŸÅÿ±ŸäŸÇŸäÿß', items: ['ÿ¥ÿ±ÿßŸÉÿßÿ™ ŸÖÿπ ÿßŸÑÿ¨ŸÖÿπŸäÿßÿ™ ÿßŸÑÿ∑ÿ®Ÿäÿ©', 'ÿ¥ÿ®ŸÉÿßÿ™ ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ° ÿßŸÑÿ¨ÿßŸÖÿπŸäŸäŸÜ', 'ÿßŸÑŸàÿµŸàŸÑ ŸÑŸÑŸÇÿ∑ÿßÿπŸäŸÜ ÿßŸÑÿπÿßŸÖ ŸàÿßŸÑÿÆÿßÿµ'] },
          ],
        },
        {
          title: 'ÿßŸÑŸÖÿ±ÿ≠ŸÑÿ© 3: ÿ¨ŸÖÿπ ÿßŸÑÿ®ŸäÿßŸÜÿßÿ™ Ÿàÿ∂ŸÖÿßŸÜ ÿßŸÑÿ¨ŸàÿØÿ©',
          items: ['ŸÜÿ¥ÿ± ÿßŸÑÿßÿ≥ÿ™ÿ®ŸäÿßŸÜÿßÿ™ ŸÖÿ™ÿπÿØÿØÿ© ÿßŸÑŸÑÿ∫ÿßÿ™ (ÿßŸÑÿπÿ±ÿ®Ÿäÿ©ÿå ÿßŸÑÿ•ŸÜÿ¨ŸÑŸäÿ≤Ÿäÿ©ÿå ÿßŸÑŸÅÿßÿ±ÿ≥Ÿäÿ©)', 'ÿßŸÑÿ™ÿ≠ŸÇŸÇ ŸÖŸÜ ÿßŸÑÿ®ŸäÿßŸÜÿßÿ™ ŸÅŸä ÿßŸÑŸàŸÇÿ™ ÿßŸÑŸÅÿπŸÑŸä', 'ÿ®ÿ±Ÿàÿ™ŸàŸÉŸàŸÑÿßÿ™ ÿßŸÑÿ™ÿ≠ŸÇŸÇ ŸÖŸÜ ŸáŸàŸäÿ© ÿßŸÑÿ£ÿ∑ÿ®ÿßÿ°', 'ŸÖÿ±ÿßŸÇÿ®ÿ© ÿßŸÑÿßŸÖÿ™ÿ´ÿßŸÑ ŸÑŸÑÿÆÿµŸàÿµŸäÿ© Ÿàÿ≠ŸÖÿßŸäÿ© ÿßŸÑÿ®ŸäÿßŸÜÿßÿ™', 'ÿßŸÑÿ™ÿ¥ŸÅŸäÿ± ÿßŸÑÿ¢ŸÖŸÜ ŸÑŸÑÿ®ŸäÿßŸÜÿßÿ™ ŸàÿßŸÑÿ™ÿÆÿ≤ŸäŸÜ', 'ŸÅÿ±ŸäŸÇ ÿ®ÿ≠ÿ´ ÿ´ŸÜÿßÿ¶Ÿä ÿßŸÑŸÑÿ∫ÿ© (ÿπÿ±ÿ®Ÿä-ÿ•ŸÜÿ¨ŸÑŸäÿ≤Ÿä)'],
        },
        {
          title: 'ÿßŸÑŸÖÿ±ÿ≠ŸÑÿ© 4: ÿßŸÑÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖÿ™ŸÇÿØŸÖ Ÿàÿ™ŸàŸÑŸäÿØ ÿßŸÑÿ±ÿ§Ÿâ',
          subsections: [
            { heading: 'ÿßŸÑÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑÿ•ÿ≠ÿµÿßÿ¶Ÿä', items: ['ŸÜŸÖÿ∞ÿ¨ÿ© ÿßŸÑÿßŸÜÿ≠ÿØÿßÿ± ŸàÿßŸÑÿ™ÿ≠ŸÑŸäŸÑÿßÿ™ ÿßŸÑÿ™ŸÜÿ®ÿ§Ÿäÿ©', 'ÿ™ŸÇÿ≥ŸäŸÖ ÿßŸÑÿ≥ŸàŸÇ Ÿàÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖÿ¨ŸÖŸàÿπÿßÿ™', 'ÿßŸÑÿ™ÿ±ŸÖŸäÿ≤ ÿßŸÑŸÖŸàÿ∂ŸàÿπŸä ŸÑŸÑÿ®ŸäÿßŸÜÿßÿ™ ÿßŸÑŸÜŸàÿπŸäÿ©', 'ÿßŸÑÿ™ÿ≠ŸÑŸäŸÑ ÿßŸÑŸÖŸÇÿßÿ±ŸÜ ÿπÿ®ÿ± ÿßŸÑÿ®ŸÑÿØÿßŸÜ'] },
            { heading: 'ÿ™ÿ≠ŸÑŸäŸÑÿßÿ™ ÿÆÿßÿµÿ© ÿ®ÿßŸÑŸÖŸÜÿ∑ŸÇÿ©', items: ['ÿ±ÿ≥ŸÖ ÿÆÿ±ÿßÿ¶ÿ∑ ŸÖÿ≥ÿßÿ±ÿßÿ™ ÿßŸÑÿπŸÑÿßÿ¨ ÿßŸÑÿ•ŸÇŸÑŸäŸÖŸäÿ©', 'ÿßŸÇÿ™ÿµÿßÿØŸäÿßÿ™ ÿßŸÑÿµÿ≠ÿ© Ÿàÿ£ÿ®ÿ≠ÿßÿ´ ÿßŸÑŸÜÿ™ÿßÿ¶ÿ¨ (HEOR)', 'ŸÜŸÖÿ∞ÿ¨ÿ© ŸÅÿπÿßŸÑŸäÿ© ÿßŸÑÿ™ŸÉŸÑŸÅÿ©', 'ÿ™ÿ≠ŸÑŸäŸÑ ŸÖÿ¥ŸáÿØ ÿßŸÑÿØŸÅÿπ ŸàÿßŸÑÿ≥ÿØÿßÿØ'] },
          ],
        },
        {
          title: 'ÿßŸÑŸÖÿ±ÿ≠ŸÑÿ© 5: ÿßŸÑÿ™ŸÇÿßÿ±Ÿäÿ± ÿßŸÑÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ŸàÿßŸÑÿ™ŸàÿµŸäÿßÿ™',
          subsections: [
            { heading: 'ÿßŸÑŸÖÿÆÿ±ÿ¨ÿßÿ™', items: ['ŸÑŸàÿ≠ÿßÿ™ ÿßŸÑŸÖÿπŸÑŸàŸÖÿßÿ™ ÿßŸÑÿ™ŸÜŸÅŸäÿ∞Ÿäÿ© (ÿπÿ±ÿ®Ÿä-ÿ•ŸÜÿ¨ŸÑŸäÿ≤Ÿä)', 'ÿ™ŸàÿµŸäÿßÿ™ ÿßÿ≥ÿ™ÿ±ÿßÿ™Ÿäÿ¨Ÿäÿ© ŸÑŸÑŸàÿµŸàŸÑ ŸÑŸÑÿ≥ŸàŸÇ', 'ÿ±ÿ§Ÿâ ÿßŸÑŸÖÿ¥ŸáÿØ ÿßŸÑÿ™ŸÜÿ∏ŸäŸÖŸä ÿßŸÑÿ•ŸÇŸÑŸäŸÖŸä', 'ÿ™ŸÇŸäŸäŸÖÿßÿ™ ŸÅÿ±ÿµ ÿßŸÑÿ≥ŸàŸÇ', 'ÿ∞ŸÉÿßÿ° ÿØŸàÿßÿ¶Ÿä ŸÇÿßÿ®ŸÑ ŸÑŸÑÿ™ŸÜŸÅŸäÿ∞', 'ÿØÿπŸÖ ÿßŸÑÿ™ŸÇÿØŸäŸÖÿßÿ™ ÿßŸÑÿ™ŸÜÿ∏ŸäŸÖŸäÿ©'] },
          ],
        },
      ],
    },
  },
} as const;

export type TranslationKey = typeof translations['en'];
